CA2711263C - Compositions and methods for the treatment of xerostomia - Google Patents
Compositions and methods for the treatment of xerostomia Download PDFInfo
- Publication number
- CA2711263C CA2711263C CA2711263A CA2711263A CA2711263C CA 2711263 C CA2711263 C CA 2711263C CA 2711263 A CA2711263 A CA 2711263A CA 2711263 A CA2711263 A CA 2711263A CA 2711263 C CA2711263 C CA 2711263C
- Authority
- CA
- Canada
- Prior art keywords
- basic amino
- composition
- amino acid
- arginine
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The present invention is directed to methods and compositions comprising a basic amino acid, e.g., arginine, for the treatment of dry mouth.
Description
COMPOSITIONS AND METHODS FOR THE TREATMENT OF
XEROSTOMIA
BACKGROUND OF THE INVENTION
100021 Dry mouth or xerostomia is an acute or chronic condition primarily caused by the lack of saliva. It may be caused by an underlying disease, such as Sjogren's syndrome, dehydration, trauma to the salivary glands, consumption of alcohol, or a side effect to medications. It has been identified as a condition increasing in the general population.
Roughly 15% to 20% of young adults complain of oral dryness, and 30 ¨ 40% of people ages 60 ¨ 80 complain of oral dryness.
1.00031 Xerostomia may cause several complications in patients. Saliva may be decreased, and may be foamy, thick and ropy. The tongue may be dry, fissured, lobulated.
and may be infected with various bacteria and yeasts. Cheeks are often dry, dull and pale. The decreased moisture in the mouth creates difficulties ill eating, as the chewing and swallowing of food is exacerbated by the lack of saliva. This rilso interferes with a person's ability to taste food, and produce speech. Furthermore, a moist mouth is beneficial in intimate human relations, which may also sulTer as a result of dry mouth, 100041 Patients suffering from xerostomia also sutler from extensive dental decay, e.g., caries, including areas not usually prone to decay, such as the lower incisors and roots. One possible explanation is that pellicle, which is present in saliva, provides a protective barrier between acids and a tooth surface, and such a barrier is reduced in the absence of saliva.
100051 There are numerous products available to alleviate dry mouth, including oral moisturizing rinses, gels and synthetic saliva sprays, but there are few products which provide an anticaries effect. Current oral products tbr the treatment of dry mouth require high concentrations of fluoride to lower their risk of developing caries, 1(10061 There is a continuing need to develop oral care compositions and methods to treat.
people suffering from dry mouth. There is also a continuing need to develop oral care compositions and methods to inhifiit the development olcaries in persons sin-flying from dry mouth. There is also a continuing need to develop oral care compositions which may aid in the consumption of foods, and production of speech in persons suffering from dry mouth.
SUMMARY OF THE INVENTION
100071 The use of basic amino acids, e.g., arginine, in toothpaste formulations is known in the art, however, the inventors have discovered an unexpected and surprising result when toothpastes comprising arginine bicarbonate are used by persons suffering from xerostomia, that is, such compositions alleviate, treat, and inhibit dry mouth. It is believed that basic amino acids, e.g., arginine may be used to prevent cavities without or without fluoride, as basic amino acid saltsõ e.g., arginine-bicarbonate, in combination with an insoluble calcium salt, typically the dentifrice abrasive mimics the protective effects of saliva against caries and provides complete protection of the tooth enamel and roots by coating the tooth.
100081 The invention thus comprises Composition 1.0, an oral care composition for the treatment, prevention, amelioration, or inhibition of dry mouth comprising an effective amount of a basic amino acid, e.g., arginine, in free or salt form, e.g., present in an amount of at least 1 % (by weight of free base) where the formulation is a dentifrice or 0.1% where the formulation is a mouth rinse; the formulation optionally further comprising one or more of i. a calcium andlor phosphate ion source, e.g., calcium carbonate and/or a soluble calcium salt, e.g., calcium chloride, calcium lactate;
ii. a soluble phosphate salt, e.g., potassium phosphate inonobasic or dibasic potassium phosphate; ancllor iii. a calcium phosphate, e.g.. dicalcium phosphate; a potassium ion source, e.g., potassium chloride, potassium phosphate monobasic or dibasic potassium phosphate, and/or potassium nitrate;
iv. a fluoride source, e.g., a soluble fluoride salt, e.g., sodium fluoride or sodium monofluorophosphate;
v. a magnesium source, e.g., magnesium chloride; a flavorant which induces saliva flow, e.g., capsacien; and/or vi. a polyol humectant, e.g., selected from glycerol, sugar alcohols (e.g., sorbitol, xylitol) and combinations thereof, for example any of the following compositions:
1Ø1. Composition 1.0 wherein the basic amino acid is arginine, lysine, citrullene, ornithine, creatine, histidine, diaminobutanoic acid, diaminoproprionic acid, salts thereof andior combinations thereof 1Ø2. Composition 1.0 or 1Ø1 wherein the basic amino acid has the L-configuration.
1Ø3. Any of the preceding compositions is provided in the form ot'a salt of a di- or tri-peptide comprising the basic amino acid.
1Ø4. Any of the preceding compositions wherein the basic amino acid is arginine.
1Ø5. Any of the preceding compositions wherein the basic amino acid is L-arginine.
1Ø6. Any of the preceding compositions wherein the basic amino acid is partially or wholly in salt form.
1Ø7. Composition 1Ø6 wherein the basic amino acid is arginine phosphate.
1Ø8. Composition 1Ø6 wherein the basic amino acid is in the form of arginine hydrochloride.
1Ø9. Composition 1Ø6 wherein the basic amino acid is arginine sulfate.
1Ø10. Composition 1Ø6 wherein the basic amino acid is arginine bicarbonate.
1Ø11. Any of the preceding compositions wherein a salt of the basic amino acid is formed in situ in the formulation by neutralization of the basic amino acid with an acid or a salt of an acid.
1Ø12. Any of the preceding compositions wherein the salt of the basic amino acid is formed by neutralization of the basic amino acid to form a premix prior to combination with the fluoride salt.
1Ø13. Any of the preceding compositions wherein the basic amino acid is present in an amount corresponding to about 0.1 -- 20%, e.g., about 1 wt. % to about 10 wt.
% of the total composition weight, the weight of the basic amino acid being calculated as free base form.
1Ø14. Composition 1Ø11 wherein the basic amino acid is present in an amount of about 7.5 wt. % of the total composition weight.
1Ø15. Composition 1.0_11 wherein the basic amino acid is present in an amount of about wt. % of the total composition weight.:
1Ø16. Composition 1Ø11 wherein the basic 'amino acid is present in an amount of about 3.75 wt. % of the total composition weight.
1Ø17. Composition 1Ø11 wherein the basic amino acid is present in an amount of about T .5 wt. % ot'the total composition weight.
1Ø18. Any of the preceding compositions wherein the fluoride salt is stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride (e.g., W-octadecyltrimethylendiamine-N,N,N'-tris(2-ethanol)-dihydrolluoride), ammonium fluoride, titanium fluoride, hexafluorosulfate, and combinations thereof.
1Ø19. Any of the preceding compositions wherein the fluoride salt is a fluorophosphate.
1Ø20. Any of the preceding composition wherein the fluoride salt is sodium monofluorophosphate.
1Ø21. Any of the preceding compositions where the fluoride salt is sodium fluoride.
1Ø22. Any of the preceding compositions wherein the fluoride salt is present in an amount of about 0.01 wt. % to about 2 wt. % of the total composition weiOrt.
1Ø23. Any of the preceding compositions wherein the fluoride salt provides fluoride ion in an amount of about 0.1 to about 0.2 wt. % of the total composition weight.
1.Ø24. Any of the preceding compositions wherein the soluble fluoride salt provides fluoride ion in an amount of from about 50 to 10,000 ppm.
1Ø25. Any of the preceding compositions which is a mouthwash having 100 to about 250 ppm available fluoride ion.
1Ø26. Any of the preceding compositions which is a dentifrice having about 750 to 2000 ppm available fluoride ion.
1Ø27. Any of the preceding compositions wherein the composition comprises 750 to 2000 ppin fluoride ion.
1Ø28. Any of the preceding compositions wherein the composition comprises 1000 to 1500 ppm fluoride ion.
1Ø29. Any of the preceding compositions wherein the composition comprises about 1450 ppm fluoride ion.
1Ø30_ Any of the preceding compositions wherein the pH is between about 6 and about 9, e.g., 6.5 and 7_4 or 7.5 and 9_ 1Ø31. Any of the preceding compositions wherein the pH is between about 6.5 and about 7.4.
1Ø32. Any of the preceding compositions wherein the pH is between about 6.8 and about 1Ø33. Any of the preceding compositions wherein the pH is approximately neutral.
1Ø34. Any of the preceding compositions further comprising an abrasive or particulate.
1Ø35. The immediately preceding composition wherein the adhesive or particulate is selected from sodium bicarbonate, calcium phosphate (e.g., dicalcium phosphate dihydrate), calcium sulfate, precipitated calcium carbonate, silica (e.g., hydrated silica), iron oxide, aluminum oxide, perlite, plastic particles, e.g., polyethylene, and combinations thereof.
1Ø36. The immediately preceding composition wherein the abrasive or particulate is selected from a calcium phosphate (e.g., dicalcium phosphate dihydrate), calcium sulfate, precipitated calcium carbonate, silica (e.g.õ hydrated silica), and combinations thereof.
1Ø37. Any of the preceding compositions comprising an abrasive in an amount of about 15 wt % to about 70 wt. % of the total composition weight.
1Ø38. Any of the preceding compositions comprising a small particle abrasive fraction of at least 5% having a d50 of <5 micrometers.
1Ø39. Any of the preceding compositions having a RDA of less than 150, e.g., about 40-140, 1Ø40. Any of the preceding compositions wherein the anionic surfactant is selected from a. water-soluble salts of higher fatty acid monoglyceride monosul fates (e.g., the sodium salt of the monosulfated monoglyceride of hydrogenated coconut oil fatty acids such as sodium N-rnethyi N-cocoyl taurate, sodium cocomo-glyceride sulfate), b. higher alkyl sulfates, e.g., sodium 'amyl sulfate, c. higher alkyl-ether sulfates, e.g., of .formula 0-13(CF12),,,CH7(0CH7CH2),,OS03X, wherein m is 6-16, e.g., 10, n is 1-6, e.g., 2, 3 or 4, and X is Na or K (for example sodium laureth-2 sulfate (CH3(Cit)10CHAOCI-I2C1-1.2)20.S03Na)), d. higher alkyl aryl sulfonates (such as sodium dodecyl benzene sulfonate (sodium lauryl benzene sulfonate)), e. higher alkyl sulfoacetates (such as sodium lauryl sulfoacetate (dodecyl sodium sulfoacetate), higher fatty acid esters of 1.,2 dihydroxy propane sulfonate, sulfocolaurate (N-2-ethyl laurate potassium sulfoacetamide) and sodium lathy]
sarcosinate), f. and mixtures thereof.
By "higher alkyl" is meant, e.g., Co alkyl, in particular embodiments, the anionic surfactant is selected from sodium lauryl sulfate and sodium ether lazy!
sulfate.
1Ø41. Any of the preceding compositions wherein the anionic surfactant is selected from sodium lauryl sulfate, sodium ether lauryl sulfate, and mixtures thereof.
1Ø42. Any of the preceding compositions wherein the anionic surfactant is present in an amount of from about 0.3% to about 4.5% by weight.
1Ø43. Any of the preceding compositions additionally comprising surfactants selected from cationic, zwitterionic, and nonionic surfactants, and mixtures thereof.
1Ø44. Any of the preceding compositions comprising at least one humectant.
1Ø45. Any of the preceding compositions comprising at least one humectant selected from glycerin, sorhitol and combinations thereof.
1Ø46. Any of the preceding compositions comprising xylital.
1.0,47. Any of the preceding compositions comprising at least one polymer.
1Ø48. Any of the preceding, compositions comprising at least one polymer selected from polyethylene glycols, polyvinylmethyl ether maleic acid copolymers, polysaccharides (e.g., cellulose derivatives, for example carboxyrnethyl cellulose, or polysaccharide gums, for example xanthan gum or carrageenan gum), and combinations thereof.
1Ø49. Any of the preceding compositions comprising gum strips or fragments.
1Ø50. Any of the preceding compositions comprising flavoring, fragrance and/or coloring.
1Ø51. Any of the preceding compositions comprising water, 1Ø52. Any of the preceding compositions comprising an antibacterial agent selected from halogenated diphenyl ether (e.g. triclosan), herbal extracts and essential oils (e.g., rosemary extract, tea extract, magnolia extract, thyniol, menthol, eucalyptol, geraniol, carvacrol, citral, hinokitol, catechol, methyl salicylate, epigallocatechin gallate, epigallocatechin, gallic acid, miswak extract, sea-buckthorn extract), bisguanide antiseptics (e.g., chlorhexidine, alexidine or octenidine), quaternary ammonium compounds (e.g., cetylpyridinium chloride (CPC), benzalkonium chloride, tetradecylpyridinium chloride (IPC), N-tetradecy1-4-ethylpyridinium chloride (TDEPC)), phenolic antiseptics, hexetidine, octenidine, sanguinarine, povidone iodine, delmopinol, sali fluor, metal ions (e.g., zinc salts, for example, zinc citrate, stannous salts, copper salts, iron salts), sanguinarine, propolis and oxygenating agents hydrogen peroxide, buffered sodium peroxyborate or peroxycarbonate), phthalic acid and its salts, monoperthalic acid and its salts and esters, ascorbyl stearate, oleoyl sarcosine, alkyl sulfate, dioctyl sulfosuccinate, salicylanilide, domiphen bromide, delmopinol, octapinol and other piperidino derivatives, nicin preparations, chlorite salts; and mixtures of any of the foregoing.
1Ø53. Any of the preceding compositions comprising an anti-inflammatory compound, e.g., an inhibitor of at least one of host pro-inflammatory factors selected from matrix metalloproteinases (MIN), cyclooxygenases (CO). PG E2, interleukin I (IL-1), IL-1[3 converting enzyme (ICE), transforming growth factor f1 I(IF-01), inducible nitric oxide synthase (iNOS), hyaluronidase, cathepsins, nuclear factor kappa B (NF-K[), and IL-1 Receptor Associated Kinase (IRAK), e,g, selected from aspirin. ketorolac, flurhiprofen, ibuprofen, naproxen, indomethacin, aspirin, Icetoprofen, piroxicam, tneclofenamic acid, nordihydoguaiaretic acid, and mixtures thereof 1Ø54. Any of the preceding compositions comprising an antioxidant, e.g., selected .from the group consisting of Co-enzyme QI 0, PQQ, Vitamin C, Vitamin E, Vitamin .
anethole-dithiothione, and mixtures thereof 1Ø55. Any of the preceding compositions wherein the anti-microbial is poorly soluble.
1Ø56. Any of the preceding compositions comprising triclosan.
1Ø57. Any of the preceding compositions comprising triclosan and xylitol.
1Ø58. Any of the preceding compositions comprising triclosan, xylitol, and precipitated.
calcium carbonate.
1Ø59. Any of the preceding compositions comprising an antibacterial agent in an amount of 0.01 -- 5 wt. % of the total composition weight.
1Ø60. Any of the preceding compositions comprising triclosan in an amount of 0.01 to 1 wt. percent of the total composition weight.
1Ø61. Any of the preceding compositions comprising triciosa.n in an amount of about 0.3% of the total composition weight.
1Ø62. Any of the preceding compositions comprising a whitening agent.
1Ø63. Any of the preceding compositions comprising a whitening agent selected from a whitening active selected from the group consisting of peroxides, metal chlorites, perborates, percarbonates, peroxyacids, hypochlorites, and combinations thereof 1Ø64. Any of the preceding compositions comprising hydrogen peroxide or a hydrogen peroxide source, e.g., urea peroxide or a peroxide salt or coinplex (e.g., such as peroxyphosphate, peroxycarbonate, perborate, peroxysilicate, or persulphate salts; for example calcium peroxyphosphate, sodium perborate, sodium carbonate peroxide, sodium peroxyphosphate, and potassium persulfate).
1Ø65. Any of the preceding compositions further comprising an agent that interferes with or prevents bacterial attachment, e.g., soibrol or chitosan.
I Ø66. Any of the preceding compositions further comprising., a source of calcium and phosphate selected from (i) calcium-glass complexes, e.g., calcium sodium phosphosilicates, and (ii) calcium-protein complexes, e.g., casein phosphopeptide-amorphous calcium phosphate.
1Ø67. Any of the preceding compositions further comprising a soluble calcium salt, e.g., selected from calcium sulfate, calcium chloride, calcium nitrate, calcium acetate, calcium lactate, and combinations thereof.
1Ø68. Any of the preceding compositions further comprising a physiologically acceptable potassium salt, e.g., potassium nitrate or potassium chloride, in an amount effective to reduce dentinal sensitivity.
1Ø69. Any of the preceding compositions comprising from about 0.1% to about 7.5% of a physiologically acceptable potassium salt, e.g., potassium nitrate and/or potassium chloride.
1Ø70. Any of the preceding compositions which is a toothpaste comprising an arginine salt, e.g., arginine hydrochloride, arginine phosphate or arginine bicarbonate; triclosan; an anionic surfactant, e.g., sodium lauryl sulfate; and a soluble fluoride salt, e.g., sodium monofluorophosphate or sodium fluoride.
1Ø71. Any of the preceding compositions effective upon application to the oral cavity, e.g., with brushing, to reduce dry mouth and/or to generate a perception of hydrating effects, and optionally to (i) reduce or inhibit formation of dental caries, e.g., caries which result from reduced saliva flow and dry mouth, (ii) reduce, repair or inhibit early enamel lesions, e.g., as detected by quantitative light-induced fluorescence (Q1...1-') or electrical caries measurement (ECM), (iii) reduce or inhibit demineralization and promote remineralization of the teeth, (iv) reduce hypersensitivity of the teeth, (v) reduce or inhibit gingivitis, (vi) promote healing of sores or cuts in the mouth, (vii) reduce levels of acid producing bacteria, (viii) to increase relative levels of arginolytic bacteria, (ix) inhibit microbial biofilm formation in the oral cavity, (x) raise andlor maintain plaque pH at levels of at least pH 5.5 following sugar challenge, (xi) reduce plaque accumulation, (xiii) enhance systemic health, including cardiovascular health, e.g., by reducing potential for systemic infection via the oral tissues, andfor (xiv) reduce erosion of the teeth, (xv) whiten the teeth., (xvi) immunize the teeth against cariogenic bacteria, (xvii) clean the teeth and oral cavity, and (xviii) reduce sleep disruption due to dry mouth.
1Ø72. A composition obtained or obtainable by combining the ingredients as set forth in any of the preceding compositions.
1Ø73. Any of the preceding compositions in a form selected from mouthrinse, toothpaste, tooth gel, tooth powder, non-abrasive gel, mousse, foam, niouth spray, lozenge, orai tablet, dental implement, and pet care product.
1Ø74. Any of the preceding compositions wherein the composition is toothpaste.
1Ø75. Any of the preceding compositions wherein the composition is a toothpaste optionally further comprising one or more of one or more of water, abrasives, surfactants, foaming agents, vitamins, polymers, enzymes, humectants, thickeners, antimicrobial agents, preservatives, flavorings, colorings and/or combinations thereof.
1Ø76. Any of the preceding compositions 1.0 ¨ 1Ø72 wherein the composition is a Mouthwash.
1Ø77. Any of the preceding compositions 1.0 ¨ 1Ø72 wherein the composition is a chewing gum.
1Ø78. Any of the preceding compositions further comprising a breath freshener, fragrance or flavoring.
[00091 Levels of active ingredients will vary based on the nature of the delivery system and the particular active. For example, the basic amino acid may be present at levels from, e.g., about 0.1 to about 20 wt %(expressed as weight of free base), e.g., about 0.1 to about 3 wt %
for a mouthrinse, about 1 to about 10 wt % for a consumer toothpaste or about 7 to about 20 wt % for a professional or prescription treatment product. Fluoride may be present at levels of, e.g,, about 25 to about 25,000 ppm, for example about 25 to about 250 ppm for a mouthrinse, about 750 to about 2,000 ppm for a consumer toothpaste, or about 2,000 to about 25,000 ppm for a professional or prescription treatment product. Levels of antibacterial will vary similarly, with levels used in toothpaste being e.g., about 5 to about 15 times greater than used in mouthrinse. For example, a triclosan mouthrinse may contain, e.g., about 0.03 wt % triclosan while a triclosan toothpaste may contain about 0.3 wt %
triclosan.
[0010i The present invention also includes Method 2.0, a method for treating, inhibiting or relieving dry mouth comprising introducing into the oral cavity to a patient in need thereof, e.g., suffering from dry mouth, an oral care composition comprising a basic amino acid in .free or salt form, e.g., any one of compositions 1.0 ¨ 1Ø78.
100.11j Additional embodiments of the present invention also include the following methods:
2.1 Of method 2.0, wherein the method is also effective (i) reduce or inhibit formation of dental caries, (ii) reduce, repair or inhibit early enamel lesions, e.g., as detected by quantitative ii2=ht-induced fluorescence (QLF) or electrical caries measurement (ECM), (iii) reduce or inhibit demineralization and promote remineralization of the teeth, (iv) reduce hypersensitivity of the teeth, (v) reduce or inhibit gingivitis, (vi) promote healing of sores or cuts in the mouth, (vii) reduce levels of acid producing bacteria, (viii) to increase relative levels of arginolytic bacteria, (ix) inhibit microbial Halm formation in the oral cavity, (x) raise and/or maintain plaque pH at levels of at least pH 5.5 following sugar challenge, (xi) reduce plaque accumulation, (xiii) enhance systemic health, including cardiovascular health, e.g., by reducing potential for systemic infection via the oral tissues, and/or (xiv) reduce erosion of the teeth, and/or (xv) clean the teeth and oral cavity.
2.2 Of methods 2.0 or 2.2 wherein the composition comprises at least 7.5%
arainine.
2.3 Of methods 2.0 ¨ 2.2 wherein the composition comprises at least 10%
arginine bicarbonate.
2.4 Of methods 2.0 ¨ 2.3 wherein the composition comprises at least 5% of a humectant.
2.5 Of methods 2M 24 wherein the patient is predisposed to dry mouth..
2.6 Of methods 2M -- 2.5 wherein the patient is suffering from dry mouth.
2.7 Of methods 2.0 2.6 wherein the patien.t has difficult), m.asticating food stuff as a result of dry mouth.
2.8 Of methods 2.0 -- 2.7 wherein the patient has difficulty swallowing as a result of dry mouth.
2.9 Of methods 2.0 - 2.8 wherein the patient has speech difficulties as a result of dry mouth.
2.10 Of methods 2.0 2.9 wherein the patient also suffers from opportunistic infection of the tongue as a result of dry mouth.
2.11 Of methods 2.0 - 2.10 wherein dry mouth is caused by a disease.
2.12 Of methods 2.0 - 2.11 wherein the patient is being treated with a medicament, said medicament causing said dry mouth.
2.13 Of methods 2.0 - 2.12 wherein dry mouth is chronic.
2.14 Of methods 2.0 - 2.13 wherein the composition comprises from about 7.5%
to about 25.0 % arginine.
2.15 Of methods 2.0 - 2.14 wherein the composition is a dentifrice.
2.16 Of methods 2.0 - 2.15 wherein the composition is a toothpaste.
2.17 Of methods 2.0 - 2.16 wherein the composition is a gel.
2.18 Of methods 2.0 - 2.17 wherein the composition is applied in the oral cavity with a tooth brush.
219 Of methods 2.0 - 2.15 wherein the composition is a mouth wash.
2.20 Of methods 2.0 - 2.19 wherein the patient performs the method more than once a day.
2.21 Of methods 2.0 - 2.20 wherein the patient performs the method daily.
100121 The present invention also contemplates th.e use of a basic amino acid in free or salt form, e.g., arginine, e.g., as provided in any of compositions 1.0 -1Ø78, for the treatment, amelioration, inhibition, and/or prevention of dry mouth.
100131 The present invention further provides the use of a basic amino acid, in free or salt form, for the manufacture of a medicament for treating, ameliorating, inhibiting or preventing dry mouth.
10014j The present invention further provides a basic amino acid, in free or salt form, for use in the treatment, amelioration, inhibition or prevention of dry mouth.
DETAILED DESCRIPTION OF THE INVENTION
1001.51 The present invention provides methods and compositions for the treatment, prevention, management, or inhibition of xerostomia in a patient suffering therefrom. In one embodiment, the patient suffers from, or is predisposed to xerostomia by disease or injury. In another embodiment, the patient suffers from, or is predisposed to xerostornia by treatment(s) of medicaments which cause xerostomia, wherein the dry mouth is a side effect of the medicament.
100161 The term "treat" or "ameliorate" is used herein to mean that administration of a composition of the present invention mitigates a condition in the patient, preferably a mammal, more preferably, a human.
100171 The term "inhibit" is used herein to mean that administration of a composition of the present invention delays the onset of a condition, e.g., by 6 hours, 12 hours, 24 hours, 48 hours, or 96 hours following the administration of the composition.
100181 The term "prevent" does not imply that a particular condition will be completely avoided in the future, rather, that the particular condition will be avoided until the patient is able to administer the compositions of the present invention at a second time point, e.g., within 12 hours, 24 hours, 48 hours, or 96 hours of an initial administration.
[00191 Without intending to be bound by a particular theory, it is hypothesized that a significant factor in the beneficial effect of arginine is that arginine may be metabolized by certain types of bacteria, e.g.. S. sunguis which are not cariogenic and which compete with cariogenic bacteria such as S. intrians, for position on the teeth and in the oral cavity. The arginoly.-tic bacteria can use arginine and other basic amino acids to produce ammonia, thereby raising the pH of their environment, while cariogenic baeteria metabolize sugar to produce lactic acid, which tends to lower the plaque pH and demineralize the teeth, ultimately leading to cavities. It is believed that regular use of a Composition of the Invention, over time, will lead to a relative increase in the arginolytic bacteria and a relative decrease in the cariogenic bacteria, resulting in a higher plaque pH
(notwithstanding, that the Composition of the Invention is itself generally pH neutral, the basic amino acid having been neutralized by an inorganic oxoacid). [t is believed that this pH-raising effect may be accomplished in compositions which are substantially free of fluoride. It is also believed that this pH-raising effect may be mechanistically separate from and complementary to the effect of fluoride in. promoting remineralization and strengthening the tooth enamel.
LOOM Concentrations of arginine in oral care compositions for anti-caries effect may be about 1.5%. Higher concentrations of arginine may be utilized for sensitive tooth relief, e.g., from about 3.75% to about 7.50% arginine, as the formulations physically occlude open dentinal tubules (pathways to pain), and provide effective pain relief.
Without being bound by theory, it is hypothesized that even higher levels of arginine, e.g., greater than 7.50%, that is, from about 7.50% to about 25%, from about 8.0% to about 20%, from about 9% to about 15%, or about 1 triil coat teeth, gums, and/or the oral cavity, leaving a perception that the mouth has been moisturized or hydrated.
100211 Compositions of the present invention may be in the form of a dentifrice comprising additional ingredients selected from one or more of water, abrasives, surfactants, foaming agents, vitamins, polymers, enzymes, humectants, thickeners, antimicrobial agents, preservatives, flavorings, colorings and/or combinations thereof [00221 The basic amino acids which can be used in the compositions and methods of the invention include not only naturally occurring basic amino acids, such as arginine, and histidine, but also any basic amino acids having a carboxyl group and an amino group in the molecule, which are water-soluble and provide an aqueous solution with a pH of 7 or greater. Accordingly, basic amino acids include, but are not limited to, arginine, lysine, citrullene, orni.thine, creatine, histidine, diaminobutanoic acid, diaminoproprionic acid, salts thereof or combinations thereof. In a particular embodiment, the basic amino acids are selected from arginine, citrullene, and ornithine. In certain embodiments, the basic amino acid is arginine, for example, Larginine, or a salt thereof.
100231 The compositions of the invention are intended for topical use in the mouth and so salts for use in the present invention should be safe for such use, in the amounts and concentrations provided. Suitable salts include salts known in the art to be pharmaceutically acceptable salts are generaily considered to be physiologically acceptable in the amounts and concentrations provided. Physiologically acceptable salts include those derived from pharm.aceutically acceptable inorganic or organic acids or bases, for example acid addition salts fortned by acids which form a physiological acceptable anion, e.g., hydrochloride or bromide salt, and base addition salts formed by bases which form a physiologically acceptable cation, for example those derived from alkali metals such as potassium and sodium or alkaline earth metals such as calcium and magnesium.
Physiologically acceptable salts may be obtained using standard procedures known in the art, for example, by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
[00241 1n various embodiments, the basic amino acid is present in an amou.nt of about 7.5 wt. % to about 25 wt. % of the total composition weight, about 1 wt. c,* to about 10 wt. % of the total composition. weight, for example about 1,5 wt. 94, 3.75 wt. %, 5 wt.
%, or 7.5 wt.
% of the total composition weight.
[00251 The oral care compositions may further include one or more fluoride ion sources, e.g., soluble fluoride salts. A wide variety of fluoride ion-yielding materials can be employed as sources of soluble fluoride in the present compositions, and such materials are known to those of skill in the art. Examples of suitable fluoride ion-yielding materials are found in U.S. Pat. No. 3,535,421, to Briner et al.; U.S. Pat. No. 4,835,155, to Parran, Jr. et 10026] Representative fluoride ion sources include, but are not limited to, stannous fluoride, sodium fluoride, potassium -fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, ammonium fluoride, and combinations thereof. In certain embodiments the fluoride ion source includes stannous fluoride, sodium fluoride, sodium monofluorophosphate as well as mixtures thereof.
100271 In certain embodiments, the oral care composition of the invention may also contain a source of fluoride ions or fluorine-providing ingredient in amounts sufficient to supply about 25 ppm to 25,000 ppm of fluoride ions, generally at least about 500 ppm, e.g..
about 500 to about 2000 ppm, e.g., about 1000 to about 1600 ppm, e.g., about 1450 ppm.
The appropriate level of fluoride will depend on the particular application. A
mouthwash, for exatnple, would typically have about 100 to about 250 ppm fluoride. A
toothpaste for general consumer use would typically have about 1000 to about 1500 ppm, with pediatric toothpaste having somewhat less. A dentifrice or coating for professional application could have as much as 5,000 or even 25,000 ppm -fluoride.
(0028) In certain embodiments, the oral care composition of the invention may contain a source of fluoride ions or fluorine-providing ingredient in amounts sufficient to supply (0029) The Compositions of the Invention may comprise a calcium phosphate abrasive, e.g., tricalcium phosphate (Ca(PO4)21, hydroxyapatite (Calo(PO4)(OH)3), or clicalcium phosphate dihydrate (Cal-11.'04 = 2H70, also sometimes relen-ed to herein as DiCal) or calcium pyrophosphate.
100301 The compositions may include one or more additional abrasives known by those of skill in the art, for example silica abrasives such as precipitated silicas having a mean particle size of up to about 20 microns, such as Zeodent I l5:. marketed by .1. M. Huber.
Other useful abrasives also include sodium metaphosphate. potassium metaphosphate, aluminum silicate, calcinated alumina, bentonite or other siliceous materials, or combinations thereof.
100311 'Fhe silica abrasive polish-Me materials useful herein. as well as the other abrasives, generally have an average particle size ranging between about 0.1 and about 30 microns, about between 5 and about 15 microns. The silica abrasives can be from precipitated silica _ CA 02711263 2012-09-11 or silica gels, such as the silica xerogels described in U.S. Pat. No.
3,538,230, to Pader et al.
and U.S. Pat. No. 3,862,307, to Digiulio. Particular silica xerogels are marketed under the trade Milne Syloid by the W. R. Grace &
Co..
Davison Chemical Division. The precipitated silica materials include those marketed by the J. M. Huber Corp. under the trade name Zeodentt, including the silica carrying the designation Zeodent 115 and (19. These silica abrasives are described in U.S.
Pat. No.
XEROSTOMIA
BACKGROUND OF THE INVENTION
100021 Dry mouth or xerostomia is an acute or chronic condition primarily caused by the lack of saliva. It may be caused by an underlying disease, such as Sjogren's syndrome, dehydration, trauma to the salivary glands, consumption of alcohol, or a side effect to medications. It has been identified as a condition increasing in the general population.
Roughly 15% to 20% of young adults complain of oral dryness, and 30 ¨ 40% of people ages 60 ¨ 80 complain of oral dryness.
1.00031 Xerostomia may cause several complications in patients. Saliva may be decreased, and may be foamy, thick and ropy. The tongue may be dry, fissured, lobulated.
and may be infected with various bacteria and yeasts. Cheeks are often dry, dull and pale. The decreased moisture in the mouth creates difficulties ill eating, as the chewing and swallowing of food is exacerbated by the lack of saliva. This rilso interferes with a person's ability to taste food, and produce speech. Furthermore, a moist mouth is beneficial in intimate human relations, which may also sulTer as a result of dry mouth, 100041 Patients suffering from xerostomia also sutler from extensive dental decay, e.g., caries, including areas not usually prone to decay, such as the lower incisors and roots. One possible explanation is that pellicle, which is present in saliva, provides a protective barrier between acids and a tooth surface, and such a barrier is reduced in the absence of saliva.
100051 There are numerous products available to alleviate dry mouth, including oral moisturizing rinses, gels and synthetic saliva sprays, but there are few products which provide an anticaries effect. Current oral products tbr the treatment of dry mouth require high concentrations of fluoride to lower their risk of developing caries, 1(10061 There is a continuing need to develop oral care compositions and methods to treat.
people suffering from dry mouth. There is also a continuing need to develop oral care compositions and methods to inhifiit the development olcaries in persons sin-flying from dry mouth. There is also a continuing need to develop oral care compositions which may aid in the consumption of foods, and production of speech in persons suffering from dry mouth.
SUMMARY OF THE INVENTION
100071 The use of basic amino acids, e.g., arginine, in toothpaste formulations is known in the art, however, the inventors have discovered an unexpected and surprising result when toothpastes comprising arginine bicarbonate are used by persons suffering from xerostomia, that is, such compositions alleviate, treat, and inhibit dry mouth. It is believed that basic amino acids, e.g., arginine may be used to prevent cavities without or without fluoride, as basic amino acid saltsõ e.g., arginine-bicarbonate, in combination with an insoluble calcium salt, typically the dentifrice abrasive mimics the protective effects of saliva against caries and provides complete protection of the tooth enamel and roots by coating the tooth.
100081 The invention thus comprises Composition 1.0, an oral care composition for the treatment, prevention, amelioration, or inhibition of dry mouth comprising an effective amount of a basic amino acid, e.g., arginine, in free or salt form, e.g., present in an amount of at least 1 % (by weight of free base) where the formulation is a dentifrice or 0.1% where the formulation is a mouth rinse; the formulation optionally further comprising one or more of i. a calcium andlor phosphate ion source, e.g., calcium carbonate and/or a soluble calcium salt, e.g., calcium chloride, calcium lactate;
ii. a soluble phosphate salt, e.g., potassium phosphate inonobasic or dibasic potassium phosphate; ancllor iii. a calcium phosphate, e.g.. dicalcium phosphate; a potassium ion source, e.g., potassium chloride, potassium phosphate monobasic or dibasic potassium phosphate, and/or potassium nitrate;
iv. a fluoride source, e.g., a soluble fluoride salt, e.g., sodium fluoride or sodium monofluorophosphate;
v. a magnesium source, e.g., magnesium chloride; a flavorant which induces saliva flow, e.g., capsacien; and/or vi. a polyol humectant, e.g., selected from glycerol, sugar alcohols (e.g., sorbitol, xylitol) and combinations thereof, for example any of the following compositions:
1Ø1. Composition 1.0 wherein the basic amino acid is arginine, lysine, citrullene, ornithine, creatine, histidine, diaminobutanoic acid, diaminoproprionic acid, salts thereof andior combinations thereof 1Ø2. Composition 1.0 or 1Ø1 wherein the basic amino acid has the L-configuration.
1Ø3. Any of the preceding compositions is provided in the form ot'a salt of a di- or tri-peptide comprising the basic amino acid.
1Ø4. Any of the preceding compositions wherein the basic amino acid is arginine.
1Ø5. Any of the preceding compositions wherein the basic amino acid is L-arginine.
1Ø6. Any of the preceding compositions wherein the basic amino acid is partially or wholly in salt form.
1Ø7. Composition 1Ø6 wherein the basic amino acid is arginine phosphate.
1Ø8. Composition 1Ø6 wherein the basic amino acid is in the form of arginine hydrochloride.
1Ø9. Composition 1Ø6 wherein the basic amino acid is arginine sulfate.
1Ø10. Composition 1Ø6 wherein the basic amino acid is arginine bicarbonate.
1Ø11. Any of the preceding compositions wherein a salt of the basic amino acid is formed in situ in the formulation by neutralization of the basic amino acid with an acid or a salt of an acid.
1Ø12. Any of the preceding compositions wherein the salt of the basic amino acid is formed by neutralization of the basic amino acid to form a premix prior to combination with the fluoride salt.
1Ø13. Any of the preceding compositions wherein the basic amino acid is present in an amount corresponding to about 0.1 -- 20%, e.g., about 1 wt. % to about 10 wt.
% of the total composition weight, the weight of the basic amino acid being calculated as free base form.
1Ø14. Composition 1Ø11 wherein the basic amino acid is present in an amount of about 7.5 wt. % of the total composition weight.
1Ø15. Composition 1.0_11 wherein the basic amino acid is present in an amount of about wt. % of the total composition weight.:
1Ø16. Composition 1Ø11 wherein the basic 'amino acid is present in an amount of about 3.75 wt. % of the total composition weight.
1Ø17. Composition 1Ø11 wherein the basic amino acid is present in an amount of about T .5 wt. % ot'the total composition weight.
1Ø18. Any of the preceding compositions wherein the fluoride salt is stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride (e.g., W-octadecyltrimethylendiamine-N,N,N'-tris(2-ethanol)-dihydrolluoride), ammonium fluoride, titanium fluoride, hexafluorosulfate, and combinations thereof.
1Ø19. Any of the preceding compositions wherein the fluoride salt is a fluorophosphate.
1Ø20. Any of the preceding composition wherein the fluoride salt is sodium monofluorophosphate.
1Ø21. Any of the preceding compositions where the fluoride salt is sodium fluoride.
1Ø22. Any of the preceding compositions wherein the fluoride salt is present in an amount of about 0.01 wt. % to about 2 wt. % of the total composition weiOrt.
1Ø23. Any of the preceding compositions wherein the fluoride salt provides fluoride ion in an amount of about 0.1 to about 0.2 wt. % of the total composition weight.
1.Ø24. Any of the preceding compositions wherein the soluble fluoride salt provides fluoride ion in an amount of from about 50 to 10,000 ppm.
1Ø25. Any of the preceding compositions which is a mouthwash having 100 to about 250 ppm available fluoride ion.
1Ø26. Any of the preceding compositions which is a dentifrice having about 750 to 2000 ppm available fluoride ion.
1Ø27. Any of the preceding compositions wherein the composition comprises 750 to 2000 ppin fluoride ion.
1Ø28. Any of the preceding compositions wherein the composition comprises 1000 to 1500 ppm fluoride ion.
1Ø29. Any of the preceding compositions wherein the composition comprises about 1450 ppm fluoride ion.
1Ø30_ Any of the preceding compositions wherein the pH is between about 6 and about 9, e.g., 6.5 and 7_4 or 7.5 and 9_ 1Ø31. Any of the preceding compositions wherein the pH is between about 6.5 and about 7.4.
1Ø32. Any of the preceding compositions wherein the pH is between about 6.8 and about 1Ø33. Any of the preceding compositions wherein the pH is approximately neutral.
1Ø34. Any of the preceding compositions further comprising an abrasive or particulate.
1Ø35. The immediately preceding composition wherein the adhesive or particulate is selected from sodium bicarbonate, calcium phosphate (e.g., dicalcium phosphate dihydrate), calcium sulfate, precipitated calcium carbonate, silica (e.g., hydrated silica), iron oxide, aluminum oxide, perlite, plastic particles, e.g., polyethylene, and combinations thereof.
1Ø36. The immediately preceding composition wherein the abrasive or particulate is selected from a calcium phosphate (e.g., dicalcium phosphate dihydrate), calcium sulfate, precipitated calcium carbonate, silica (e.g.õ hydrated silica), and combinations thereof.
1Ø37. Any of the preceding compositions comprising an abrasive in an amount of about 15 wt % to about 70 wt. % of the total composition weight.
1Ø38. Any of the preceding compositions comprising a small particle abrasive fraction of at least 5% having a d50 of <5 micrometers.
1Ø39. Any of the preceding compositions having a RDA of less than 150, e.g., about 40-140, 1Ø40. Any of the preceding compositions wherein the anionic surfactant is selected from a. water-soluble salts of higher fatty acid monoglyceride monosul fates (e.g., the sodium salt of the monosulfated monoglyceride of hydrogenated coconut oil fatty acids such as sodium N-rnethyi N-cocoyl taurate, sodium cocomo-glyceride sulfate), b. higher alkyl sulfates, e.g., sodium 'amyl sulfate, c. higher alkyl-ether sulfates, e.g., of .formula 0-13(CF12),,,CH7(0CH7CH2),,OS03X, wherein m is 6-16, e.g., 10, n is 1-6, e.g., 2, 3 or 4, and X is Na or K (for example sodium laureth-2 sulfate (CH3(Cit)10CHAOCI-I2C1-1.2)20.S03Na)), d. higher alkyl aryl sulfonates (such as sodium dodecyl benzene sulfonate (sodium lauryl benzene sulfonate)), e. higher alkyl sulfoacetates (such as sodium lauryl sulfoacetate (dodecyl sodium sulfoacetate), higher fatty acid esters of 1.,2 dihydroxy propane sulfonate, sulfocolaurate (N-2-ethyl laurate potassium sulfoacetamide) and sodium lathy]
sarcosinate), f. and mixtures thereof.
By "higher alkyl" is meant, e.g., Co alkyl, in particular embodiments, the anionic surfactant is selected from sodium lauryl sulfate and sodium ether lazy!
sulfate.
1Ø41. Any of the preceding compositions wherein the anionic surfactant is selected from sodium lauryl sulfate, sodium ether lauryl sulfate, and mixtures thereof.
1Ø42. Any of the preceding compositions wherein the anionic surfactant is present in an amount of from about 0.3% to about 4.5% by weight.
1Ø43. Any of the preceding compositions additionally comprising surfactants selected from cationic, zwitterionic, and nonionic surfactants, and mixtures thereof.
1Ø44. Any of the preceding compositions comprising at least one humectant.
1Ø45. Any of the preceding compositions comprising at least one humectant selected from glycerin, sorhitol and combinations thereof.
1Ø46. Any of the preceding compositions comprising xylital.
1.0,47. Any of the preceding compositions comprising at least one polymer.
1Ø48. Any of the preceding, compositions comprising at least one polymer selected from polyethylene glycols, polyvinylmethyl ether maleic acid copolymers, polysaccharides (e.g., cellulose derivatives, for example carboxyrnethyl cellulose, or polysaccharide gums, for example xanthan gum or carrageenan gum), and combinations thereof.
1Ø49. Any of the preceding compositions comprising gum strips or fragments.
1Ø50. Any of the preceding compositions comprising flavoring, fragrance and/or coloring.
1Ø51. Any of the preceding compositions comprising water, 1Ø52. Any of the preceding compositions comprising an antibacterial agent selected from halogenated diphenyl ether (e.g. triclosan), herbal extracts and essential oils (e.g., rosemary extract, tea extract, magnolia extract, thyniol, menthol, eucalyptol, geraniol, carvacrol, citral, hinokitol, catechol, methyl salicylate, epigallocatechin gallate, epigallocatechin, gallic acid, miswak extract, sea-buckthorn extract), bisguanide antiseptics (e.g., chlorhexidine, alexidine or octenidine), quaternary ammonium compounds (e.g., cetylpyridinium chloride (CPC), benzalkonium chloride, tetradecylpyridinium chloride (IPC), N-tetradecy1-4-ethylpyridinium chloride (TDEPC)), phenolic antiseptics, hexetidine, octenidine, sanguinarine, povidone iodine, delmopinol, sali fluor, metal ions (e.g., zinc salts, for example, zinc citrate, stannous salts, copper salts, iron salts), sanguinarine, propolis and oxygenating agents hydrogen peroxide, buffered sodium peroxyborate or peroxycarbonate), phthalic acid and its salts, monoperthalic acid and its salts and esters, ascorbyl stearate, oleoyl sarcosine, alkyl sulfate, dioctyl sulfosuccinate, salicylanilide, domiphen bromide, delmopinol, octapinol and other piperidino derivatives, nicin preparations, chlorite salts; and mixtures of any of the foregoing.
1Ø53. Any of the preceding compositions comprising an anti-inflammatory compound, e.g., an inhibitor of at least one of host pro-inflammatory factors selected from matrix metalloproteinases (MIN), cyclooxygenases (CO). PG E2, interleukin I (IL-1), IL-1[3 converting enzyme (ICE), transforming growth factor f1 I(IF-01), inducible nitric oxide synthase (iNOS), hyaluronidase, cathepsins, nuclear factor kappa B (NF-K[), and IL-1 Receptor Associated Kinase (IRAK), e,g, selected from aspirin. ketorolac, flurhiprofen, ibuprofen, naproxen, indomethacin, aspirin, Icetoprofen, piroxicam, tneclofenamic acid, nordihydoguaiaretic acid, and mixtures thereof 1Ø54. Any of the preceding compositions comprising an antioxidant, e.g., selected .from the group consisting of Co-enzyme QI 0, PQQ, Vitamin C, Vitamin E, Vitamin .
anethole-dithiothione, and mixtures thereof 1Ø55. Any of the preceding compositions wherein the anti-microbial is poorly soluble.
1Ø56. Any of the preceding compositions comprising triclosan.
1Ø57. Any of the preceding compositions comprising triclosan and xylitol.
1Ø58. Any of the preceding compositions comprising triclosan, xylitol, and precipitated.
calcium carbonate.
1Ø59. Any of the preceding compositions comprising an antibacterial agent in an amount of 0.01 -- 5 wt. % of the total composition weight.
1Ø60. Any of the preceding compositions comprising triclosan in an amount of 0.01 to 1 wt. percent of the total composition weight.
1Ø61. Any of the preceding compositions comprising triciosa.n in an amount of about 0.3% of the total composition weight.
1Ø62. Any of the preceding compositions comprising a whitening agent.
1Ø63. Any of the preceding compositions comprising a whitening agent selected from a whitening active selected from the group consisting of peroxides, metal chlorites, perborates, percarbonates, peroxyacids, hypochlorites, and combinations thereof 1Ø64. Any of the preceding compositions comprising hydrogen peroxide or a hydrogen peroxide source, e.g., urea peroxide or a peroxide salt or coinplex (e.g., such as peroxyphosphate, peroxycarbonate, perborate, peroxysilicate, or persulphate salts; for example calcium peroxyphosphate, sodium perborate, sodium carbonate peroxide, sodium peroxyphosphate, and potassium persulfate).
1Ø65. Any of the preceding compositions further comprising an agent that interferes with or prevents bacterial attachment, e.g., soibrol or chitosan.
I Ø66. Any of the preceding compositions further comprising., a source of calcium and phosphate selected from (i) calcium-glass complexes, e.g., calcium sodium phosphosilicates, and (ii) calcium-protein complexes, e.g., casein phosphopeptide-amorphous calcium phosphate.
1Ø67. Any of the preceding compositions further comprising a soluble calcium salt, e.g., selected from calcium sulfate, calcium chloride, calcium nitrate, calcium acetate, calcium lactate, and combinations thereof.
1Ø68. Any of the preceding compositions further comprising a physiologically acceptable potassium salt, e.g., potassium nitrate or potassium chloride, in an amount effective to reduce dentinal sensitivity.
1Ø69. Any of the preceding compositions comprising from about 0.1% to about 7.5% of a physiologically acceptable potassium salt, e.g., potassium nitrate and/or potassium chloride.
1Ø70. Any of the preceding compositions which is a toothpaste comprising an arginine salt, e.g., arginine hydrochloride, arginine phosphate or arginine bicarbonate; triclosan; an anionic surfactant, e.g., sodium lauryl sulfate; and a soluble fluoride salt, e.g., sodium monofluorophosphate or sodium fluoride.
1Ø71. Any of the preceding compositions effective upon application to the oral cavity, e.g., with brushing, to reduce dry mouth and/or to generate a perception of hydrating effects, and optionally to (i) reduce or inhibit formation of dental caries, e.g., caries which result from reduced saliva flow and dry mouth, (ii) reduce, repair or inhibit early enamel lesions, e.g., as detected by quantitative light-induced fluorescence (Q1...1-') or electrical caries measurement (ECM), (iii) reduce or inhibit demineralization and promote remineralization of the teeth, (iv) reduce hypersensitivity of the teeth, (v) reduce or inhibit gingivitis, (vi) promote healing of sores or cuts in the mouth, (vii) reduce levels of acid producing bacteria, (viii) to increase relative levels of arginolytic bacteria, (ix) inhibit microbial biofilm formation in the oral cavity, (x) raise andlor maintain plaque pH at levels of at least pH 5.5 following sugar challenge, (xi) reduce plaque accumulation, (xiii) enhance systemic health, including cardiovascular health, e.g., by reducing potential for systemic infection via the oral tissues, andfor (xiv) reduce erosion of the teeth, (xv) whiten the teeth., (xvi) immunize the teeth against cariogenic bacteria, (xvii) clean the teeth and oral cavity, and (xviii) reduce sleep disruption due to dry mouth.
1Ø72. A composition obtained or obtainable by combining the ingredients as set forth in any of the preceding compositions.
1Ø73. Any of the preceding compositions in a form selected from mouthrinse, toothpaste, tooth gel, tooth powder, non-abrasive gel, mousse, foam, niouth spray, lozenge, orai tablet, dental implement, and pet care product.
1Ø74. Any of the preceding compositions wherein the composition is toothpaste.
1Ø75. Any of the preceding compositions wherein the composition is a toothpaste optionally further comprising one or more of one or more of water, abrasives, surfactants, foaming agents, vitamins, polymers, enzymes, humectants, thickeners, antimicrobial agents, preservatives, flavorings, colorings and/or combinations thereof.
1Ø76. Any of the preceding compositions 1.0 ¨ 1Ø72 wherein the composition is a Mouthwash.
1Ø77. Any of the preceding compositions 1.0 ¨ 1Ø72 wherein the composition is a chewing gum.
1Ø78. Any of the preceding compositions further comprising a breath freshener, fragrance or flavoring.
[00091 Levels of active ingredients will vary based on the nature of the delivery system and the particular active. For example, the basic amino acid may be present at levels from, e.g., about 0.1 to about 20 wt %(expressed as weight of free base), e.g., about 0.1 to about 3 wt %
for a mouthrinse, about 1 to about 10 wt % for a consumer toothpaste or about 7 to about 20 wt % for a professional or prescription treatment product. Fluoride may be present at levels of, e.g,, about 25 to about 25,000 ppm, for example about 25 to about 250 ppm for a mouthrinse, about 750 to about 2,000 ppm for a consumer toothpaste, or about 2,000 to about 25,000 ppm for a professional or prescription treatment product. Levels of antibacterial will vary similarly, with levels used in toothpaste being e.g., about 5 to about 15 times greater than used in mouthrinse. For example, a triclosan mouthrinse may contain, e.g., about 0.03 wt % triclosan while a triclosan toothpaste may contain about 0.3 wt %
triclosan.
[0010i The present invention also includes Method 2.0, a method for treating, inhibiting or relieving dry mouth comprising introducing into the oral cavity to a patient in need thereof, e.g., suffering from dry mouth, an oral care composition comprising a basic amino acid in .free or salt form, e.g., any one of compositions 1.0 ¨ 1Ø78.
100.11j Additional embodiments of the present invention also include the following methods:
2.1 Of method 2.0, wherein the method is also effective (i) reduce or inhibit formation of dental caries, (ii) reduce, repair or inhibit early enamel lesions, e.g., as detected by quantitative ii2=ht-induced fluorescence (QLF) or electrical caries measurement (ECM), (iii) reduce or inhibit demineralization and promote remineralization of the teeth, (iv) reduce hypersensitivity of the teeth, (v) reduce or inhibit gingivitis, (vi) promote healing of sores or cuts in the mouth, (vii) reduce levels of acid producing bacteria, (viii) to increase relative levels of arginolytic bacteria, (ix) inhibit microbial Halm formation in the oral cavity, (x) raise and/or maintain plaque pH at levels of at least pH 5.5 following sugar challenge, (xi) reduce plaque accumulation, (xiii) enhance systemic health, including cardiovascular health, e.g., by reducing potential for systemic infection via the oral tissues, and/or (xiv) reduce erosion of the teeth, and/or (xv) clean the teeth and oral cavity.
2.2 Of methods 2.0 or 2.2 wherein the composition comprises at least 7.5%
arainine.
2.3 Of methods 2.0 ¨ 2.2 wherein the composition comprises at least 10%
arginine bicarbonate.
2.4 Of methods 2.0 ¨ 2.3 wherein the composition comprises at least 5% of a humectant.
2.5 Of methods 2M 24 wherein the patient is predisposed to dry mouth..
2.6 Of methods 2M -- 2.5 wherein the patient is suffering from dry mouth.
2.7 Of methods 2.0 2.6 wherein the patien.t has difficult), m.asticating food stuff as a result of dry mouth.
2.8 Of methods 2.0 -- 2.7 wherein the patient has difficulty swallowing as a result of dry mouth.
2.9 Of methods 2.0 - 2.8 wherein the patient has speech difficulties as a result of dry mouth.
2.10 Of methods 2.0 2.9 wherein the patient also suffers from opportunistic infection of the tongue as a result of dry mouth.
2.11 Of methods 2.0 - 2.10 wherein dry mouth is caused by a disease.
2.12 Of methods 2.0 - 2.11 wherein the patient is being treated with a medicament, said medicament causing said dry mouth.
2.13 Of methods 2.0 - 2.12 wherein dry mouth is chronic.
2.14 Of methods 2.0 - 2.13 wherein the composition comprises from about 7.5%
to about 25.0 % arginine.
2.15 Of methods 2.0 - 2.14 wherein the composition is a dentifrice.
2.16 Of methods 2.0 - 2.15 wherein the composition is a toothpaste.
2.17 Of methods 2.0 - 2.16 wherein the composition is a gel.
2.18 Of methods 2.0 - 2.17 wherein the composition is applied in the oral cavity with a tooth brush.
219 Of methods 2.0 - 2.15 wherein the composition is a mouth wash.
2.20 Of methods 2.0 - 2.19 wherein the patient performs the method more than once a day.
2.21 Of methods 2.0 - 2.20 wherein the patient performs the method daily.
100121 The present invention also contemplates th.e use of a basic amino acid in free or salt form, e.g., arginine, e.g., as provided in any of compositions 1.0 -1Ø78, for the treatment, amelioration, inhibition, and/or prevention of dry mouth.
100131 The present invention further provides the use of a basic amino acid, in free or salt form, for the manufacture of a medicament for treating, ameliorating, inhibiting or preventing dry mouth.
10014j The present invention further provides a basic amino acid, in free or salt form, for use in the treatment, amelioration, inhibition or prevention of dry mouth.
DETAILED DESCRIPTION OF THE INVENTION
1001.51 The present invention provides methods and compositions for the treatment, prevention, management, or inhibition of xerostomia in a patient suffering therefrom. In one embodiment, the patient suffers from, or is predisposed to xerostomia by disease or injury. In another embodiment, the patient suffers from, or is predisposed to xerostornia by treatment(s) of medicaments which cause xerostomia, wherein the dry mouth is a side effect of the medicament.
100161 The term "treat" or "ameliorate" is used herein to mean that administration of a composition of the present invention mitigates a condition in the patient, preferably a mammal, more preferably, a human.
100171 The term "inhibit" is used herein to mean that administration of a composition of the present invention delays the onset of a condition, e.g., by 6 hours, 12 hours, 24 hours, 48 hours, or 96 hours following the administration of the composition.
100181 The term "prevent" does not imply that a particular condition will be completely avoided in the future, rather, that the particular condition will be avoided until the patient is able to administer the compositions of the present invention at a second time point, e.g., within 12 hours, 24 hours, 48 hours, or 96 hours of an initial administration.
[00191 Without intending to be bound by a particular theory, it is hypothesized that a significant factor in the beneficial effect of arginine is that arginine may be metabolized by certain types of bacteria, e.g.. S. sunguis which are not cariogenic and which compete with cariogenic bacteria such as S. intrians, for position on the teeth and in the oral cavity. The arginoly.-tic bacteria can use arginine and other basic amino acids to produce ammonia, thereby raising the pH of their environment, while cariogenic baeteria metabolize sugar to produce lactic acid, which tends to lower the plaque pH and demineralize the teeth, ultimately leading to cavities. It is believed that regular use of a Composition of the Invention, over time, will lead to a relative increase in the arginolytic bacteria and a relative decrease in the cariogenic bacteria, resulting in a higher plaque pH
(notwithstanding, that the Composition of the Invention is itself generally pH neutral, the basic amino acid having been neutralized by an inorganic oxoacid). [t is believed that this pH-raising effect may be accomplished in compositions which are substantially free of fluoride. It is also believed that this pH-raising effect may be mechanistically separate from and complementary to the effect of fluoride in. promoting remineralization and strengthening the tooth enamel.
LOOM Concentrations of arginine in oral care compositions for anti-caries effect may be about 1.5%. Higher concentrations of arginine may be utilized for sensitive tooth relief, e.g., from about 3.75% to about 7.50% arginine, as the formulations physically occlude open dentinal tubules (pathways to pain), and provide effective pain relief.
Without being bound by theory, it is hypothesized that even higher levels of arginine, e.g., greater than 7.50%, that is, from about 7.50% to about 25%, from about 8.0% to about 20%, from about 9% to about 15%, or about 1 triil coat teeth, gums, and/or the oral cavity, leaving a perception that the mouth has been moisturized or hydrated.
100211 Compositions of the present invention may be in the form of a dentifrice comprising additional ingredients selected from one or more of water, abrasives, surfactants, foaming agents, vitamins, polymers, enzymes, humectants, thickeners, antimicrobial agents, preservatives, flavorings, colorings and/or combinations thereof [00221 The basic amino acids which can be used in the compositions and methods of the invention include not only naturally occurring basic amino acids, such as arginine, and histidine, but also any basic amino acids having a carboxyl group and an amino group in the molecule, which are water-soluble and provide an aqueous solution with a pH of 7 or greater. Accordingly, basic amino acids include, but are not limited to, arginine, lysine, citrullene, orni.thine, creatine, histidine, diaminobutanoic acid, diaminoproprionic acid, salts thereof or combinations thereof. In a particular embodiment, the basic amino acids are selected from arginine, citrullene, and ornithine. In certain embodiments, the basic amino acid is arginine, for example, Larginine, or a salt thereof.
100231 The compositions of the invention are intended for topical use in the mouth and so salts for use in the present invention should be safe for such use, in the amounts and concentrations provided. Suitable salts include salts known in the art to be pharmaceutically acceptable salts are generaily considered to be physiologically acceptable in the amounts and concentrations provided. Physiologically acceptable salts include those derived from pharm.aceutically acceptable inorganic or organic acids or bases, for example acid addition salts fortned by acids which form a physiological acceptable anion, e.g., hydrochloride or bromide salt, and base addition salts formed by bases which form a physiologically acceptable cation, for example those derived from alkali metals such as potassium and sodium or alkaline earth metals such as calcium and magnesium.
Physiologically acceptable salts may be obtained using standard procedures known in the art, for example, by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
[00241 1n various embodiments, the basic amino acid is present in an amou.nt of about 7.5 wt. % to about 25 wt. % of the total composition weight, about 1 wt. c,* to about 10 wt. % of the total composition. weight, for example about 1,5 wt. 94, 3.75 wt. %, 5 wt.
%, or 7.5 wt.
% of the total composition weight.
[00251 The oral care compositions may further include one or more fluoride ion sources, e.g., soluble fluoride salts. A wide variety of fluoride ion-yielding materials can be employed as sources of soluble fluoride in the present compositions, and such materials are known to those of skill in the art. Examples of suitable fluoride ion-yielding materials are found in U.S. Pat. No. 3,535,421, to Briner et al.; U.S. Pat. No. 4,835,155, to Parran, Jr. et 10026] Representative fluoride ion sources include, but are not limited to, stannous fluoride, sodium fluoride, potassium -fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, ammonium fluoride, and combinations thereof. In certain embodiments the fluoride ion source includes stannous fluoride, sodium fluoride, sodium monofluorophosphate as well as mixtures thereof.
100271 In certain embodiments, the oral care composition of the invention may also contain a source of fluoride ions or fluorine-providing ingredient in amounts sufficient to supply about 25 ppm to 25,000 ppm of fluoride ions, generally at least about 500 ppm, e.g..
about 500 to about 2000 ppm, e.g., about 1000 to about 1600 ppm, e.g., about 1450 ppm.
The appropriate level of fluoride will depend on the particular application. A
mouthwash, for exatnple, would typically have about 100 to about 250 ppm fluoride. A
toothpaste for general consumer use would typically have about 1000 to about 1500 ppm, with pediatric toothpaste having somewhat less. A dentifrice or coating for professional application could have as much as 5,000 or even 25,000 ppm -fluoride.
(0028) In certain embodiments, the oral care composition of the invention may contain a source of fluoride ions or fluorine-providing ingredient in amounts sufficient to supply (0029) The Compositions of the Invention may comprise a calcium phosphate abrasive, e.g., tricalcium phosphate (Ca(PO4)21, hydroxyapatite (Calo(PO4)(OH)3), or clicalcium phosphate dihydrate (Cal-11.'04 = 2H70, also sometimes relen-ed to herein as DiCal) or calcium pyrophosphate.
100301 The compositions may include one or more additional abrasives known by those of skill in the art, for example silica abrasives such as precipitated silicas having a mean particle size of up to about 20 microns, such as Zeodent I l5:. marketed by .1. M. Huber.
Other useful abrasives also include sodium metaphosphate. potassium metaphosphate, aluminum silicate, calcinated alumina, bentonite or other siliceous materials, or combinations thereof.
100311 'Fhe silica abrasive polish-Me materials useful herein. as well as the other abrasives, generally have an average particle size ranging between about 0.1 and about 30 microns, about between 5 and about 15 microns. The silica abrasives can be from precipitated silica _ CA 02711263 2012-09-11 or silica gels, such as the silica xerogels described in U.S. Pat. No.
3,538,230, to Pader et al.
and U.S. Pat. No. 3,862,307, to Digiulio. Particular silica xerogels are marketed under the trade Milne Syloid by the W. R. Grace &
Co..
Davison Chemical Division. The precipitated silica materials include those marketed by the J. M. Huber Corp. under the trade name Zeodentt, including the silica carrying the designation Zeodent 115 and (19. These silica abrasives are described in U.S.
Pat. No.
4,340,583, to Wason.
[0032] In certain embodiments, abrasive materials useful in the practice of the oral care compositions in accordance with the invention include silica gels and precipitated amorphous silica having an oil absorption value of about less than 100 cc/100 g silica and in the range of about 45 cc/100 g to about 70 cc/100 g silica. Oil absorption values are measured using the ASTA Rub-Out Method D281. In certain embodiments, the silicas are colloidal particles having an average particle size of about 3 microns to about 12 microns, and about 5 to about 10 microns.
100331 In particular embodiments, the particulate or abrasive materials comprise a large fraction of very small particles, e.g., having a d50 less than about 5 microns, for example small particle silica (SYS) having a d50 of about 3 to about 4 microns, for example Sorbosil AC43it (lneos). Such small particles are particularly useful in formulations targeted at = reducing hypersensitivity. The small particle component may be present in combination with a second larger particle abrasive. In certain embodiments, for example, the forinulation comprises about 3 to about 8% SPS and about 25 to about 45% of a conventional abrasive.
100341 Low oil absorption silica abrasives particularly useful in the practice of the invention are marketed under the trade designation Sylodent )(Vag' by Davison Chemical Division of W.R. Grace & Co., Baltimore, Md. 21203. Sylodent 650 XWA1', a silica hydrogel composed of particles of colloidal silica having a water content of about 29% by weight averaging about 7 to about 10 microns in diameter,' and an oil absorption of less than about 70 ccil 00 g of silica is an example of a low oil absorption silica abrasive useful in the practice of the present invention. The abrasive is present in the oral care composition of the present invention at a concentration of about l 0 Co about 60% bv weight., in other embodiment about 20 to about 45% by weight. and in another emboditrient about 30 to about 50% by weight.
[00351 The oral care compositions of the invention also may include an tgent to increase the amount of foam that is produced when the oral cavity is brushed. Such agents are CA 02711263 2012-0.9-11 known to those of skill in the art. Illustrative examples of agents that increase the amount offoam include, but are not limited to polyoxyethylene and certain polymers including, but not limited to, alginate polymers.
100361 The polyoxyethylene may increase the amount of foam and the thickness of the foam generated by the oral care carrier component of the present invention.
Polyoxyethylene is also commonly known as polyethylene glycol ("PEG") or polyethylene oxide. The polyoxyethylenes suitable for this invention will have a molecular weight of about 200,000 to about 7,000,000. In one embodiment the molecular weight will be about 600,000 to about 2.000,000 and in another embodiment about 800.000 to about 1,000,000.
Polyox is the trade name for the high molecular weight polyoxyethylene produced by Union Carbide.
[0037) The polyoxyethylene may be present in an amount of about 1% to about 90%, in one embodiment about 5% to about 50% and in another embodiment about 1.0% to about 20% by weight of the oral care carrier component of the oral care compositions of the present invention. The dosage of foaming agent in the oral care composition (i.e., a single dose) is about 0.01 to about 0.9 % by weight, about 0.05 to about 0.5% by weight, and in another embodiment about 0.1 to about 0.2 % by weight.
100381 Another agent optionally included in the oral care composition of the invention is a surfactant or a mixture of compatible surfactants. Suitable surfactants are those which are reasonably stable throughout a wide pii range, for example, anionic, cationic, nonionic or zwitterionic surfactants. Suitable surfactants are described more fully, for example, in U.S.
Pat. No. 3,959,458, to Agricola et al.; U.S. Pat. No. 3,937,807. to Haefele;
and U.S. Pat. No.
4,051,234. to Gieske et al . A preferred surfactant is sodium lauryl sulfate.
[00391 The surfactant or mixtures of compatible surfactants can be present in the compositions of the present invention in about 0.1% to about 5.0%, in another embodiment about 0.3% to about 3.0% and in another embodiment about 0.5% to about 2.0% by weight of the total composition.
100401 liie oral care compositions of the invention may also include a flavoring agent.
Flavoring agents which are used in the practice oldie present invention arc known hy those of skill in the art, and may include essential oils as well as various flavoring aldehydes, esters. alcohols. and similar materials. The flavoring agent is incorporated in the oral composition at a concentration of about 0.1 to about 5% by weight and about 0.5 to about 1.5% by weight. The dosage of flavoring agent in the individual oral care composition dosage (i.e., a single dose) is about 0.001 to 0.05% by weight and in another embodiment about 0.005 to 0.015 % by weight.
100411 The oral care compositions and methods of the invention also may optionally include one or more chelating agents able to complex calcium found in the cell walls of the bacteria. Binding of this calcium weakens the bacterial cell wall and augments bacterial lysis. Chelating agents are well known by those of skill in the art, e.g., soluble pyrophosphates, either in hydrated or unhydrated -forms. An effective amount of pyrophosphate salt useful in the present composition is generally enough to provide at least 1.0 wt. A pyrophosphate ions, about 1.5 xvt. % to about 6 wt. %. about 3.5 wt. % to about 6 wt. % of such ions.
100421 The oral care compositions or methods of the invention also optionally include one or more polymers, which are known by those of skill in the. art. Such polymers may include polyethylene glycols, polyvinyltnethyl ether maleic acid copolymers, polysaccharides (e,g., cellulose derivatives, for example carboxymethyl cellulose, or polysaccharide gums, for example xanthan gum or carrageenan gum). Polymers suitable for use may include Gantrez AN 139(M.W. 500.000), AN 119 (M.W. 250,000) and S-97 Phartnaceutical Grade (M.W.
70,000), ofGAF Chemicals Corporation. Suitable polymers may also include homopolymers of substituted acrylarnides andjor homopolymers of unsaturated sulfonic acids and salts thereof, in particular where polymers are based on unsaturated sullonic acids selected from acrylamidoalykane sulfonic i)cids such as 2-acryiamide 2 methylpropane sulfonic acid having a molecular weight of about 1,000 to about 2,000,000, described in U.S. Pat. No. 4,842,8,17, Jun. 27. 1989 to Zahid. Another useful class of polymeric agents includes polyamino acids, particularly those containing proportions of anionic surface-active amino acids such as aspartic acid, alutamic acid and phosphoserine, as disclosed in U.S. Pat. No. 4,866,161 Sikes et al..
10043] The compositions and methods of the present invention may also comprise thickening material to provide a desirable consistency or to stabilize or enhance the performance of the formulation. Such thickening materials are known by those of skill in the art. e.g., carboxyvinyl polymers, can.ageenan, hydroxyethy I cellulose and water soluble salts of cellulose ethers such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethy i cellulose. 'Natural gums such as karaya, gum arabic, and gum tragacanth can -also be incorporated. Colloidal magnesium aluminum silicate or finely divided silica can be used as component. of the thickening composition to further improve the composition's t, texture. In certain embodiments, thickening agents in an amount of about 0.5%
to about 5.0% by weight of the total composition are used.
100441 The compositions and methods of the present invention may also optionally include one or more enzymes. Useful enzymes include those known by those of skill in the art, and may include proteases, glucanohydrolases, endoglycosidases, amylases, mutanases, lipases and mucinases or compatible mixtures thereof. Enzymes suitable for use in the present invention are disclosed in U.S. Pat. No. 5õ0-00,939 to Dring et al., U.S. Pat. No.
4,992,420; U.S. Pat. No. 4,355,022; U.S. Pat. No. 4,154,815; U.S. Pat. No.
4,058,595; U.S.
Pat. No. 3,991,177; and U.S. Pat. No. 3,696,191. An enzyme of a mixture of several compatible enzynics in the cui-tent invention constitutes about 0.002% to about 2.0% in one embodiment or about 0.05% to about 1.5% in another embodiment or in yet another embodiment about 0.1% to about 0.5%.
100451 Water may also be present in the oral compositions of the invention.
Water, employed in the preparation of commercial oral compositions is preferably deionized and free of organic impurities. Water commonly makes up the balance of the compositions, and includes the free water which is added plus that amount which is introduced with other materials such as with sorbitol or any components of the invention.
100461 'Me present invention may comprise humectant to prevent the composition from hardening upon exposure to air, and to aid in the hydration of the mouth.
Certain hu.mectants can also impart desirable sweetness or flavor to dentifrice compositions. The humectant, on a pure humectant basis, generally includes about 15% to about 70% in one embodiment or about 30% to about 65% in another embodiment by weight of the dentifrice C omposition.
100471 Suitable humectants include edible polyhydric alcohols such as glycerine, sorbitol, = xylitol. propylene glycol as well as other polyols and mixtures of these humectants.
Mixtures oí glycerine and sorbitol may be used in certain embodiments as the humectant component of the toothpaste cotnpositions herein.
100481 In addition to the above described components, the embodiments of this invention can contain a variety of optional dentifrice ingredients some of which are described below.
Optional ingredients include, for example. but are not limited to, adhesives, sudsing agents.
flavoring agents. sweetening agents, additional antiplaque agents. abrasives, and coloring agents. These and other optional (-_:omponents are further described in U.S.
Pat. No.
5.004,5T7, to N4ajeti; U.S. Pat. No. 3.959,458 TO AgriCOia et al. and U.S.
Pat. No. 3,937,07, to Ilaefele, [00491 The compositions and methods according to the invention are useful to a method to treat dry mouth, and optionally protect the teeth by facilitating repair and remineraliz.ation, in particular to reduce or inhibit formation of dental caries, reduce or inhibit demineralization and promote remineralization of the teeth, reduce hypersensitivity of the teeth, and reduce, repair or inhibit pre-carious lesions of the enamel, e.g., as detected by quantitative light-induced fluorescence (QI.,F) or electrical caries measurement (ECM).
Quantitative light-induced fluorescence is a visible light system that permits early detection of pre-caries lesions in the enamel. Normal teeth fluoresce in visible light;
demineralized teeth do not or do so only to a lesser degree. The area ademineralization can be quantified and its progress monitored. Electrical conductance measurement exploits the fact that the fluid-tilled tubules exposed upon demineralization and erosion of the enamel conduct electricity. An increase in the conductance of the patient's teeth therefore may indicate demineralization. The Compositions of the invention are thus useful in a method to reduce pre-carious lesions of the enamel (as measured by QLF or ECM) relative to a composition lacking effective amounts of fluorine and/or arginine.
100501 As such the Compositions of the Invention are useful not only for treating dry mouth, but also for treating other oral conditions in the mouth, and to clean the oral cavity and provide improved methods of promoting oral health.
190511 'Enhancing oral health also provides benefits in systemic health, as the oral tissues can be gateways for systemic infections. Good oral health is associated with systemic health, including cardiovascular health. The compositions and methods of the invention provide particular benefits because basic amino acidsõ especially arginine, are sources of nitrogen which supply NO synthesis pathways and thus enhance microcirculation in the oral tissues. Providing a less acidic oral environment is also helpful in reducing gastric distress and creates an environment less favorable to Heliobacter, which is associated with gastric ulcers. Arginine in particular is required for high expression of specific immune cell receptors, for example T-cell receptors, so that arginine can enhance an effective immune response. The compositions and methods of the invention are thus useful to enhance systemic health, including cardiovascular health.
100521 The compositions and methods according to the invention can be incorporated into oral compositions for the care a the mouth and teeth such as toothpastes, transparent pastes, gels, mouth rinses, sprays and chewing gum [0053] As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the ranee can be selected as the terminus of the range.
In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls. It is understood that when formulations are described, they may be described in terms of their ingredients, as is common in the art, notwithstanding that these ingredients may react with one another in the actual formulation as it is made, stored and used, and such products are intended to be covered by the formulations described.
[0054] The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
Example 1 ¨ Toothpaste formulation 100551 A toothpaste composition is prepared from the following ingredients to produce a toothpaste having 7.50% wt. arginine.
=
Deionized Water 7.400 Glycerin 21.000 Carboxymethyl cellulose 0.500 =
Saccharin 0.250 Basic amino acid salt (arginine bicarbonate) = I 0.000 Calcium carbonate 29.000 Hydrated silica 31.000 Flavor 0.750 Color solution (1% FMK Blue #1) 0.100 Example 2 ¨ Patient study 100561 Eight patients suffering from dry mouth are provided with the composition of EXAMPLE 1. The patients are instructed to brush with the composition of twice a day, and record observations on their dry mouth condition prior to usage, at day 4, and at day S.
10057i Prior to use of the toothpaste, 7 patients suffer front dry mouth throughout the whole day; lbur patients also suffer from dry lips and tongue; two patients have difficulty swallowing; 3 patients have difficulty eating, talking and sleeping due to dry mouth.
=
=
[00581 At day 4, most patients feel the composition hydrates their mouth, and left the mouth feeling comfortable. No patient thinks the composition made the mouth drier. 25%
of patients indicate that the mouth felt smooth, moist, and hydrated.
[00591 M day 8, most patients believe the composition provides dry mouth relief, leaving their mouth feeling moist, pleasant and smooth.
Example 3: Artificial Saliva Formulation comprising Arginine [00601 An artificial saliva formulation is prepared from the following ingredients:
RAW MATERIAL WEIGHT %
Deionized Water 96.26815 Xylitol 2.00000 1L-Arginine 0.50000 Hydroxyethyl cellulose 0.43000 Flavor 040000 ?vie:thy' paraben 0.20000 Dibasic potassium phosphate 0.08000 Potassium chloride 0.06200 Potassium phosphate monobasic 0.04300 Calcium chloride dihydrate 0.01.000 Magnesium chloride 0.00590 Food colorant 0.00050 Sodium fluoride 0.00045 TOTAL 100.00000
[0032] In certain embodiments, abrasive materials useful in the practice of the oral care compositions in accordance with the invention include silica gels and precipitated amorphous silica having an oil absorption value of about less than 100 cc/100 g silica and in the range of about 45 cc/100 g to about 70 cc/100 g silica. Oil absorption values are measured using the ASTA Rub-Out Method D281. In certain embodiments, the silicas are colloidal particles having an average particle size of about 3 microns to about 12 microns, and about 5 to about 10 microns.
100331 In particular embodiments, the particulate or abrasive materials comprise a large fraction of very small particles, e.g., having a d50 less than about 5 microns, for example small particle silica (SYS) having a d50 of about 3 to about 4 microns, for example Sorbosil AC43it (lneos). Such small particles are particularly useful in formulations targeted at = reducing hypersensitivity. The small particle component may be present in combination with a second larger particle abrasive. In certain embodiments, for example, the forinulation comprises about 3 to about 8% SPS and about 25 to about 45% of a conventional abrasive.
100341 Low oil absorption silica abrasives particularly useful in the practice of the invention are marketed under the trade designation Sylodent )(Vag' by Davison Chemical Division of W.R. Grace & Co., Baltimore, Md. 21203. Sylodent 650 XWA1', a silica hydrogel composed of particles of colloidal silica having a water content of about 29% by weight averaging about 7 to about 10 microns in diameter,' and an oil absorption of less than about 70 ccil 00 g of silica is an example of a low oil absorption silica abrasive useful in the practice of the present invention. The abrasive is present in the oral care composition of the present invention at a concentration of about l 0 Co about 60% bv weight., in other embodiment about 20 to about 45% by weight. and in another emboditrient about 30 to about 50% by weight.
[00351 The oral care compositions of the invention also may include an tgent to increase the amount of foam that is produced when the oral cavity is brushed. Such agents are CA 02711263 2012-0.9-11 known to those of skill in the art. Illustrative examples of agents that increase the amount offoam include, but are not limited to polyoxyethylene and certain polymers including, but not limited to, alginate polymers.
100361 The polyoxyethylene may increase the amount of foam and the thickness of the foam generated by the oral care carrier component of the present invention.
Polyoxyethylene is also commonly known as polyethylene glycol ("PEG") or polyethylene oxide. The polyoxyethylenes suitable for this invention will have a molecular weight of about 200,000 to about 7,000,000. In one embodiment the molecular weight will be about 600,000 to about 2.000,000 and in another embodiment about 800.000 to about 1,000,000.
Polyox is the trade name for the high molecular weight polyoxyethylene produced by Union Carbide.
[0037) The polyoxyethylene may be present in an amount of about 1% to about 90%, in one embodiment about 5% to about 50% and in another embodiment about 1.0% to about 20% by weight of the oral care carrier component of the oral care compositions of the present invention. The dosage of foaming agent in the oral care composition (i.e., a single dose) is about 0.01 to about 0.9 % by weight, about 0.05 to about 0.5% by weight, and in another embodiment about 0.1 to about 0.2 % by weight.
100381 Another agent optionally included in the oral care composition of the invention is a surfactant or a mixture of compatible surfactants. Suitable surfactants are those which are reasonably stable throughout a wide pii range, for example, anionic, cationic, nonionic or zwitterionic surfactants. Suitable surfactants are described more fully, for example, in U.S.
Pat. No. 3,959,458, to Agricola et al.; U.S. Pat. No. 3,937,807. to Haefele;
and U.S. Pat. No.
4,051,234. to Gieske et al . A preferred surfactant is sodium lauryl sulfate.
[00391 The surfactant or mixtures of compatible surfactants can be present in the compositions of the present invention in about 0.1% to about 5.0%, in another embodiment about 0.3% to about 3.0% and in another embodiment about 0.5% to about 2.0% by weight of the total composition.
100401 liie oral care compositions of the invention may also include a flavoring agent.
Flavoring agents which are used in the practice oldie present invention arc known hy those of skill in the art, and may include essential oils as well as various flavoring aldehydes, esters. alcohols. and similar materials. The flavoring agent is incorporated in the oral composition at a concentration of about 0.1 to about 5% by weight and about 0.5 to about 1.5% by weight. The dosage of flavoring agent in the individual oral care composition dosage (i.e., a single dose) is about 0.001 to 0.05% by weight and in another embodiment about 0.005 to 0.015 % by weight.
100411 The oral care compositions and methods of the invention also may optionally include one or more chelating agents able to complex calcium found in the cell walls of the bacteria. Binding of this calcium weakens the bacterial cell wall and augments bacterial lysis. Chelating agents are well known by those of skill in the art, e.g., soluble pyrophosphates, either in hydrated or unhydrated -forms. An effective amount of pyrophosphate salt useful in the present composition is generally enough to provide at least 1.0 wt. A pyrophosphate ions, about 1.5 xvt. % to about 6 wt. %. about 3.5 wt. % to about 6 wt. % of such ions.
100421 The oral care compositions or methods of the invention also optionally include one or more polymers, which are known by those of skill in the. art. Such polymers may include polyethylene glycols, polyvinyltnethyl ether maleic acid copolymers, polysaccharides (e,g., cellulose derivatives, for example carboxymethyl cellulose, or polysaccharide gums, for example xanthan gum or carrageenan gum). Polymers suitable for use may include Gantrez AN 139(M.W. 500.000), AN 119 (M.W. 250,000) and S-97 Phartnaceutical Grade (M.W.
70,000), ofGAF Chemicals Corporation. Suitable polymers may also include homopolymers of substituted acrylarnides andjor homopolymers of unsaturated sulfonic acids and salts thereof, in particular where polymers are based on unsaturated sullonic acids selected from acrylamidoalykane sulfonic i)cids such as 2-acryiamide 2 methylpropane sulfonic acid having a molecular weight of about 1,000 to about 2,000,000, described in U.S. Pat. No. 4,842,8,17, Jun. 27. 1989 to Zahid. Another useful class of polymeric agents includes polyamino acids, particularly those containing proportions of anionic surface-active amino acids such as aspartic acid, alutamic acid and phosphoserine, as disclosed in U.S. Pat. No. 4,866,161 Sikes et al..
10043] The compositions and methods of the present invention may also comprise thickening material to provide a desirable consistency or to stabilize or enhance the performance of the formulation. Such thickening materials are known by those of skill in the art. e.g., carboxyvinyl polymers, can.ageenan, hydroxyethy I cellulose and water soluble salts of cellulose ethers such as sodium carboxymethyl cellulose and sodium carboxymethyl hydroxyethy i cellulose. 'Natural gums such as karaya, gum arabic, and gum tragacanth can -also be incorporated. Colloidal magnesium aluminum silicate or finely divided silica can be used as component. of the thickening composition to further improve the composition's t, texture. In certain embodiments, thickening agents in an amount of about 0.5%
to about 5.0% by weight of the total composition are used.
100441 The compositions and methods of the present invention may also optionally include one or more enzymes. Useful enzymes include those known by those of skill in the art, and may include proteases, glucanohydrolases, endoglycosidases, amylases, mutanases, lipases and mucinases or compatible mixtures thereof. Enzymes suitable for use in the present invention are disclosed in U.S. Pat. No. 5õ0-00,939 to Dring et al., U.S. Pat. No.
4,992,420; U.S. Pat. No. 4,355,022; U.S. Pat. No. 4,154,815; U.S. Pat. No.
4,058,595; U.S.
Pat. No. 3,991,177; and U.S. Pat. No. 3,696,191. An enzyme of a mixture of several compatible enzynics in the cui-tent invention constitutes about 0.002% to about 2.0% in one embodiment or about 0.05% to about 1.5% in another embodiment or in yet another embodiment about 0.1% to about 0.5%.
100451 Water may also be present in the oral compositions of the invention.
Water, employed in the preparation of commercial oral compositions is preferably deionized and free of organic impurities. Water commonly makes up the balance of the compositions, and includes the free water which is added plus that amount which is introduced with other materials such as with sorbitol or any components of the invention.
100461 'Me present invention may comprise humectant to prevent the composition from hardening upon exposure to air, and to aid in the hydration of the mouth.
Certain hu.mectants can also impart desirable sweetness or flavor to dentifrice compositions. The humectant, on a pure humectant basis, generally includes about 15% to about 70% in one embodiment or about 30% to about 65% in another embodiment by weight of the dentifrice C omposition.
100471 Suitable humectants include edible polyhydric alcohols such as glycerine, sorbitol, = xylitol. propylene glycol as well as other polyols and mixtures of these humectants.
Mixtures oí glycerine and sorbitol may be used in certain embodiments as the humectant component of the toothpaste cotnpositions herein.
100481 In addition to the above described components, the embodiments of this invention can contain a variety of optional dentifrice ingredients some of which are described below.
Optional ingredients include, for example. but are not limited to, adhesives, sudsing agents.
flavoring agents. sweetening agents, additional antiplaque agents. abrasives, and coloring agents. These and other optional (-_:omponents are further described in U.S.
Pat. No.
5.004,5T7, to N4ajeti; U.S. Pat. No. 3.959,458 TO AgriCOia et al. and U.S.
Pat. No. 3,937,07, to Ilaefele, [00491 The compositions and methods according to the invention are useful to a method to treat dry mouth, and optionally protect the teeth by facilitating repair and remineraliz.ation, in particular to reduce or inhibit formation of dental caries, reduce or inhibit demineralization and promote remineralization of the teeth, reduce hypersensitivity of the teeth, and reduce, repair or inhibit pre-carious lesions of the enamel, e.g., as detected by quantitative light-induced fluorescence (QI.,F) or electrical caries measurement (ECM).
Quantitative light-induced fluorescence is a visible light system that permits early detection of pre-caries lesions in the enamel. Normal teeth fluoresce in visible light;
demineralized teeth do not or do so only to a lesser degree. The area ademineralization can be quantified and its progress monitored. Electrical conductance measurement exploits the fact that the fluid-tilled tubules exposed upon demineralization and erosion of the enamel conduct electricity. An increase in the conductance of the patient's teeth therefore may indicate demineralization. The Compositions of the invention are thus useful in a method to reduce pre-carious lesions of the enamel (as measured by QLF or ECM) relative to a composition lacking effective amounts of fluorine and/or arginine.
100501 As such the Compositions of the Invention are useful not only for treating dry mouth, but also for treating other oral conditions in the mouth, and to clean the oral cavity and provide improved methods of promoting oral health.
190511 'Enhancing oral health also provides benefits in systemic health, as the oral tissues can be gateways for systemic infections. Good oral health is associated with systemic health, including cardiovascular health. The compositions and methods of the invention provide particular benefits because basic amino acidsõ especially arginine, are sources of nitrogen which supply NO synthesis pathways and thus enhance microcirculation in the oral tissues. Providing a less acidic oral environment is also helpful in reducing gastric distress and creates an environment less favorable to Heliobacter, which is associated with gastric ulcers. Arginine in particular is required for high expression of specific immune cell receptors, for example T-cell receptors, so that arginine can enhance an effective immune response. The compositions and methods of the invention are thus useful to enhance systemic health, including cardiovascular health.
100521 The compositions and methods according to the invention can be incorporated into oral compositions for the care a the mouth and teeth such as toothpastes, transparent pastes, gels, mouth rinses, sprays and chewing gum [0053] As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the ranee can be selected as the terminus of the range.
In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls. It is understood that when formulations are described, they may be described in terms of their ingredients, as is common in the art, notwithstanding that these ingredients may react with one another in the actual formulation as it is made, stored and used, and such products are intended to be covered by the formulations described.
[0054] The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
Example 1 ¨ Toothpaste formulation 100551 A toothpaste composition is prepared from the following ingredients to produce a toothpaste having 7.50% wt. arginine.
=
Deionized Water 7.400 Glycerin 21.000 Carboxymethyl cellulose 0.500 =
Saccharin 0.250 Basic amino acid salt (arginine bicarbonate) = I 0.000 Calcium carbonate 29.000 Hydrated silica 31.000 Flavor 0.750 Color solution (1% FMK Blue #1) 0.100 Example 2 ¨ Patient study 100561 Eight patients suffering from dry mouth are provided with the composition of EXAMPLE 1. The patients are instructed to brush with the composition of twice a day, and record observations on their dry mouth condition prior to usage, at day 4, and at day S.
10057i Prior to use of the toothpaste, 7 patients suffer front dry mouth throughout the whole day; lbur patients also suffer from dry lips and tongue; two patients have difficulty swallowing; 3 patients have difficulty eating, talking and sleeping due to dry mouth.
=
=
[00581 At day 4, most patients feel the composition hydrates their mouth, and left the mouth feeling comfortable. No patient thinks the composition made the mouth drier. 25%
of patients indicate that the mouth felt smooth, moist, and hydrated.
[00591 M day 8, most patients believe the composition provides dry mouth relief, leaving their mouth feeling moist, pleasant and smooth.
Example 3: Artificial Saliva Formulation comprising Arginine [00601 An artificial saliva formulation is prepared from the following ingredients:
RAW MATERIAL WEIGHT %
Deionized Water 96.26815 Xylitol 2.00000 1L-Arginine 0.50000 Hydroxyethyl cellulose 0.43000 Flavor 040000 ?vie:thy' paraben 0.20000 Dibasic potassium phosphate 0.08000 Potassium chloride 0.06200 Potassium phosphate monobasic 0.04300 Calcium chloride dihydrate 0.01.000 Magnesium chloride 0.00590 Food colorant 0.00050 Sodium fluoride 0.00045 TOTAL 100.00000
Claims (21)
1. Use of a composition comprising a basic amino acid, in free or salt form, for the treatment, amelioration, inhibition, or prevention of dry mouth.
2. The use of claim 1, wherein the basic amino acid is arginine.
3. The use of claim 2, wherein the arginine is in the form of arginine bicarbonate.
4. The use of claim 1, 2 or 3, wherein the composition further comprises one or more of:
(a) a calcium ion source;
(b) a phosphate ion source;
(c) a potassium ion source;
(d) a magnesium ion source;
(e) a fluoride source;
(f) a flavorant which promotes saliva flow; and (g) a polyol humectant.
(a) a calcium ion source;
(b) a phosphate ion source;
(c) a potassium ion source;
(d) a magnesium ion source;
(e) a fluoride source;
(f) a flavorant which promotes saliva flow; and (g) a polyol humectant.
5. The use of any one of claims 1 to 4, wherein the composition is a dentifrice.
6. The use of any one of claims 1 to 4, wherein the composition is a mouth rinse.
7. The use of claim 6, wherein the mouthrinse is an artificial saliva comprising ions selected from the group consisting of calcium, phosphate, potassium, magnesium, and combinations thereof.
8. Use of a basic amino acid, in free or salt form, for the manufacture of a medicament for the treatment, amelioration, inhibition or prevention of dry mouth.
9. The use of claim 8, wherein the basic amino acid is arginine.
10. The use of claim 9, wherein the arginine is in the form of arginine bicarbonate.
11. The use of any one of claims 8 to 10, wherein the medicament further comprises one or more of:
(a) a calcium ion source;
(b) a phosphate ion source;
(c) a potassium ion source;
(d) a magnesium ion source;
(e) a fluoride source;
(f) a flavorant which promotes saliva flow; and (g) a polyol humectant.
(a) a calcium ion source;
(b) a phosphate ion source;
(c) a potassium ion source;
(d) a magnesium ion source;
(e) a fluoride source;
(f) a flavorant which promotes saliva flow; and (g) a polyol humectant.
12. The use of claim 11, wherein the medicament is a dentifrice.
13. The use of claim 11, wherein the medicament is a mouth rinse.
14. The use of claim 13, wherein the mouthrinse is an artificial saliva comprising ions selected from the group consisting of calcium, phosphate, potassium, magnesium, and combinations thereof.
15. A basic amino acid, in free or salt form, for use in the treatment, amelioration, inhibition or prevention of dry mouth.
16. The basic amino acid of claim 15, wherein the basic amino acid is arginine.
17. The basic amino acid of claim 16, wherein the arginine is in the form of arginine bicarbonate.
18. The basic amino acid of any one of claims 15 to 18, in a composition which further comprises one or more of:
(a) a calcium ion source, (b) a phosphate ion source, (c) a potassium ion source, (d) a magnesium ion source, (e) a fluoride source;
(f) a flavorant which promotes saliva flow; and (g) a polyol humectant.
(a) a calcium ion source, (b) a phosphate ion source, (c) a potassium ion source, (d) a magnesium ion source, (e) a fluoride source;
(f) a flavorant which promotes saliva flow; and (g) a polyol humectant.
19. The basic amino acid of claim 18, wherein the composition is a dentifrice.
20. The basic amino acid of claim 18, wherein the composition is a mouth rinse.
21. The basic amino acid of claim 20, wherein the mouthrinse is an artificial saliva comprising the ions selected from calcium, phosphate, potassium, magnesium, and combinations thereof.
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2743108P | 2008-02-08 | 2008-02-08 | |
| US2743208P | 2008-02-08 | 2008-02-08 | |
| US2743508P | 2008-02-08 | 2008-02-08 | |
| US2742008P | 2008-02-08 | 2008-02-08 | |
| US61/027,435 | 2008-02-08 | ||
| US61/027,420 | 2008-02-08 | ||
| US61/027,432 | 2008-02-08 | ||
| US61/027,431 | 2008-02-08 | ||
| US2744208P | 2008-02-09 | 2008-02-09 | |
| US2743808P | 2008-02-09 | 2008-02-09 | |
| US61/027,438 | 2008-02-09 | ||
| US61/027,442 | 2008-02-09 | ||
| PCT/US2009/033291 WO2009100265A2 (en) | 2008-02-08 | 2009-02-06 | Compositions and methods for the treatment of xerostomia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2711263A1 CA2711263A1 (en) | 2009-08-13 |
| CA2711263C true CA2711263C (en) | 2014-01-21 |
Family
ID=40952694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2711263A Expired - Fee Related CA2711263C (en) | 2008-02-08 | 2009-02-06 | Compositions and methods for the treatment of xerostomia |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10471283B2 (en) |
| EP (1) | EP2249789A4 (en) |
| JP (1) | JP2011511793A (en) |
| CN (2) | CN104398396A (en) |
| AR (1) | AR070355A1 (en) |
| AU (1) | AU2009212321B2 (en) |
| BR (1) | BRPI0906462A2 (en) |
| CA (1) | CA2711263C (en) |
| MX (1) | MX2010005007A (en) |
| MY (1) | MY157782A (en) |
| RU (2) | RU2491928C1 (en) |
| TW (1) | TWI409084B (en) |
| WO (1) | WO2009100265A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2605744B1 (en) * | 2010-08-18 | 2017-11-01 | Colgate-Palmolive Company | Oral care product and methods of use and manufacture thereof |
| US9717929B2 (en) * | 2010-12-07 | 2017-08-01 | Colgate-Palmolive Company | Dentifrice compositions containing calcium silicate and a basic amino acid |
| MX341906B (en) | 2010-12-23 | 2016-09-06 | Colgate Palmolive Co | Aqueous oral care composition comprising xanthan gum, cellulose gum and carbomer. |
| CN102085369B (en) * | 2011-01-28 | 2012-07-04 | 武汉耦合医学科技有限责任公司 | Medical gel product for xerostomia and preparation method thereof |
| AU2014243929B2 (en) | 2013-03-14 | 2019-01-17 | 3 In 1 Dental Pllc | Compositions for treatment of xerostomia and for tooth treatment |
| RU2538699C1 (en) * | 2013-11-29 | 2015-01-10 | Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") | Pharmaceutical composition for treating individuals suffering xerostomia |
| RU2554504C1 (en) * | 2014-02-20 | 2015-06-27 | Андрей Константинович Иорданишвили | Method of treating drug sialoadenopathy |
| CN104840958B (en) * | 2015-05-28 | 2018-03-30 | 广州帝奇医药技术有限公司 | Artificial transmucosal composition and its preparation method and application |
| JP2015221814A (en) * | 2015-07-10 | 2015-12-10 | コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−Ｐａｌｍｏｌｉｖｅ Ｃｏｍｐａｎｙ | Oral care product, and usage and manufacturing method of the same |
| CN105616205A (en) * | 2016-01-26 | 2016-06-01 | 浙江浙北药业有限公司 | White-strip composition |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA696470A (en) * | 1962-02-15 | 1964-10-20 | The Procter & Gamble Company | Oral compositions for caries prophylaxis |
| US3538230A (en) | 1966-12-05 | 1970-11-03 | Lever Brothers Ltd | Oral compositions containing silica xerogels as cleaning and polishing agents |
| US3678154A (en) * | 1968-07-01 | 1972-07-18 | Procter & Gamble | Oral compositions for calculus retardation |
| US3535421A (en) | 1968-07-11 | 1970-10-20 | Procter & Gamble | Oral compositions for calculus retardation |
| US4154815A (en) * | 1970-04-01 | 1979-05-15 | Lever Brothers Company | Zinc and enzyme toothpowder dentifrice |
| US3696191A (en) * | 1970-11-10 | 1972-10-03 | Monsanto Co | Dental creams containing enzymes |
| US3932608A (en) * | 1971-08-30 | 1976-01-13 | General Mills, Inc. | Food composition |
| US3943241A (en) * | 1971-08-30 | 1976-03-09 | General Mills, Inc. | Cariostatic composition |
| US4058595A (en) * | 1971-10-13 | 1977-11-15 | Colgate-Palmolive Company | Stabilized toothpastes containing an enzyme |
| US3932605A (en) * | 1972-06-12 | 1976-01-13 | Jaroslav Vit | Dental treatment |
| US3988434A (en) * | 1972-08-07 | 1976-10-26 | Schole Murray L | Dental preparation |
| US3959458A (en) | 1973-02-09 | 1976-05-25 | The Procter & Gamble Company | Oral compositions for calculus retardation |
| US3937807A (en) | 1973-03-06 | 1976-02-10 | The Procter & Gamble Company | Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies |
| US4025616A (en) * | 1973-03-06 | 1977-05-24 | The Procter & Gamble Company | Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies |
| US3862307A (en) | 1973-04-09 | 1975-01-21 | Procter & Gamble | Dentifrices containing a cationic therapeutic agent and improved silica abrasive |
| US4100269A (en) * | 1973-06-28 | 1978-07-11 | Lever Brothers Company | Anticalculus dentifrice |
| US4022880A (en) * | 1973-09-26 | 1977-05-10 | Lever Brothers Company | Anticalculus composition |
| US3925543A (en) * | 1973-11-01 | 1975-12-09 | Colgate Palmolive Co | Antibacterial oral compositions containing preservative-antioxidants |
| US3991177A (en) | 1973-11-27 | 1976-11-09 | Colgate-Palmolive Company | Oral compositions containing dextranase |
| US4011309A (en) * | 1975-01-20 | 1977-03-08 | Marion Laboratories, Inc. | Dentifrice composition and method for desensitizing sensitive teeth |
| US4051234A (en) * | 1975-06-06 | 1977-09-27 | The Procter & Gamble Company | Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies |
| US4064138A (en) * | 1975-11-12 | 1977-12-20 | General Mills, Inc. | Amino acid derivatives |
| USRE31181E (en) * | 1976-06-18 | 1983-03-15 | Means and method for improving natural defenses against caries | |
| ZA773318B (en) * | 1976-06-18 | 1978-04-26 | I Kleinberg | Means and method for improving natural defenses against caries |
| US4108979A (en) * | 1976-08-02 | 1978-08-22 | Indiana University Foundation | Dentifrice preparations comprising aluminum and a compatible abrasive |
| US4108981A (en) * | 1976-08-02 | 1978-08-22 | Indiana University Foundation | Alkaline oral compositions comprising aluminum and a carboxylic acid |
| US4042680A (en) * | 1976-08-02 | 1977-08-16 | Indiana University Foundation | Anticariogenic maloaluminate complexes |
| US4146607A (en) * | 1977-11-07 | 1979-03-27 | Lever Brothers Company | Synergistic anti-plaque mixture with tetradecylamine plus aluminum and/or zinc |
| US4160821A (en) * | 1978-02-27 | 1979-07-10 | Johnson & Johnson | Treatment for gingivitis |
| GB1573727A (en) * | 1978-05-19 | 1980-08-28 | Colgate Palmolive Co | Dentifrices |
| US4216961A (en) * | 1978-08-04 | 1980-08-12 | Mcquillan Mary J | Table baseball apparatus |
| US4225579A (en) * | 1979-02-27 | 1980-09-30 | Israel Kleinberg | Means and method for improving defenses against caries |
| US4340583A (en) | 1979-05-23 | 1982-07-20 | J. M. Huber Corporation | High fluoride compatibility dentifrice abrasives and compositions |
| US4339432A (en) * | 1979-06-20 | 1982-07-13 | Lever Brothers Company | Oral mouthwash containing zinc and glycine |
| US4269822A (en) * | 1979-07-20 | 1981-05-26 | Laclede Professional Products, Inc. | Antiseptic dentifrice |
| JPS5835965B2 (en) * | 1979-07-31 | 1983-08-05 | ライオン株式会社 | Oral composition |
| JPS5846483B2 (en) * | 1979-09-20 | 1983-10-17 | ライオン株式会社 | Oral composition |
| US4355022A (en) * | 1981-07-01 | 1982-10-19 | Interon, Inc. | Method of dental treatment |
| US4532124A (en) * | 1981-08-19 | 1985-07-30 | Development Finance Corporation Of New Zealand | Dental rinse |
| JPS58118509A (en) * | 1981-12-29 | 1983-07-14 | Lion Corp | Composition for oral cavity |
| US4885155A (en) | 1982-06-22 | 1989-12-05 | The Procter & Gamble Company | Anticalculus compositions using pyrophosphate salt |
| US4477429A (en) * | 1982-08-26 | 1984-10-16 | Johnson & Johnson Products, Inc. | Oral compositions comprising N.sup.α -alkyl derivatives of arginine |
| US4725576A (en) * | 1983-12-29 | 1988-02-16 | Research Foundation Of State University Of New York | Fungicidal polypeptide compositions containing L-histidine and methods for use therefore |
| US4528181A (en) * | 1984-02-01 | 1985-07-09 | Colgate-Palmolive Company | Dentifrice containing dual sources of fluoride |
| US5334617A (en) * | 1984-03-19 | 1994-08-02 | The Rockefeller University | Amino acids useful as inhibitors of the advanced glycosylation of proteins |
| GB8411731D0 (en) * | 1984-05-09 | 1984-06-13 | Unilever Plc | Oral compositions |
| US5000939A (en) * | 1984-06-12 | 1991-03-19 | Colgate-Palmolive Company | Dentifrice containing stabilized enzyme |
| JPH0742219B2 (en) * | 1984-07-26 | 1995-05-10 | ライオン株式会社 | Oral composition |
| US4538990A (en) * | 1984-09-24 | 1985-09-03 | Medical College Of Ga. Research Institute, Inc. | Method of decreasing the permeability of a dental cavity |
| CH671879A5 (en) * | 1987-02-26 | 1989-10-13 | Nestle Sa | |
| US4820506A (en) * | 1987-05-01 | 1989-04-11 | Research Foundation, State University Of New York | Salivary stimulant |
| US4866161A (en) * | 1987-08-24 | 1989-09-12 | University Of South Alabama | Inhibition of tartar deposition by polyanionic/hydrophobic peptides and derivatives thereof which have a clustered block copolymer structure |
| US5004597A (en) * | 1987-09-14 | 1991-04-02 | The Procter & Gamble Company | Oral compositions comprising stannous flouride and stannous gluconate |
| GB8729564D0 (en) * | 1987-12-18 | 1988-02-03 | Unilever Plc | Oral compositions |
| US4842847A (en) | 1987-12-21 | 1989-06-27 | The B. F. Goodrich Company | Dental calculus inhibiting compositions |
| US5438076A (en) * | 1988-05-03 | 1995-08-01 | Perio Products, Ltd. | Liquid polymer composition, and method of use |
| US5096700A (en) * | 1990-09-28 | 1992-03-17 | The Procter & Gamble Company | Halogenated aminohexanoates and aminobutyrates antimicrobial agents |
| US5370865A (en) * | 1992-05-15 | 1994-12-06 | Kao Corporation | Composition for use in oral cavity |
| US5286480A (en) * | 1992-06-29 | 1994-02-15 | The Procter & Gamble Company | Use of N-acetylated amino acid complexes in oral care compositions |
| US5496558A (en) * | 1993-03-02 | 1996-03-05 | Block Drug Company Inc. | Solid form xerostomia product |
| EP0704533A1 (en) * | 1994-09-30 | 1996-04-03 | Bayer Ag | An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus |
| WO1997002802A1 (en) * | 1995-07-10 | 1997-01-30 | Unilever N.V. | Self-heating dentifrice |
| JPH0958053A (en) | 1995-08-29 | 1997-03-04 | Ricoh Co Ltd | Image forming apparatus |
| CA2184802C (en) * | 1995-10-10 | 2007-07-31 | Karl-Heinz Bender | Process for manufacture of imidazo benzodiazepine derivatives |
| CN1093756C (en) | 1996-01-31 | 2002-11-06 | 尤尼利弗公司 | Oral preparations |
| US5762911A (en) * | 1996-03-05 | 1998-06-09 | The Research Foundation Of State University Of New York | Anti-caries oral compositions |
| US6488961B1 (en) * | 1996-09-20 | 2002-12-03 | Ethypharm, Inc. | Effervescent granules and methods for their preparation |
| US5906811A (en) * | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
| US5922346A (en) * | 1997-12-01 | 1999-07-13 | Thione International, Inc. | Antioxidant preparation |
| US6805883B2 (en) * | 1998-03-12 | 2004-10-19 | Mars, Incorporated | Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide |
| US5997301A (en) * | 1998-10-20 | 1999-12-07 | Linden; Lars Ake | Treatment of tooth surfaces and substances therefor |
| US6436370B1 (en) * | 1999-06-23 | 2002-08-20 | The Research Foundation Of State University Of New York | Dental anti-hypersensitivity composition and method |
| GB2354441A (en) * | 1999-08-06 | 2001-03-28 | Mccormack Ltd | Composition for treating dentine hypersensitivity |
| US6558654B2 (en) | 2000-04-11 | 2003-05-06 | Mclaughlin Gerald | Composition and method for whitening teeth |
| US8283135B2 (en) * | 2000-06-30 | 2012-10-09 | The Procter & Gamble Company | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
| US20020081360A1 (en) * | 2000-12-27 | 2002-06-27 | Andreas Burgard | Salts of L-amino acid having improved taste and their preparation |
| RU2005102604A (en) | 2002-07-03 | 2005-09-10 | Перикор Сайенс, Инк. (Us) | COMPOSITION OF HYALURONIC ACID AND METHODS OF APPLICATION |
| US20050215473A1 (en) * | 2003-05-09 | 2005-09-29 | Enrique Alvarez | Prophylactic and therapeutic uses of FGF-20 in radiation protection |
| CA2566507A1 (en) * | 2004-05-10 | 2006-07-13 | Curagen Corporation | Prophylactic and therapeutic uses of fgf-20 in radiation protection |
| MX2007001384A (en) | 2004-08-02 | 2007-04-19 | Glaxo Group Ltd | Novel composition for xerostomia. |
| EP2103306B1 (en) * | 2004-09-17 | 2012-06-06 | Ajinomoto Co., Inc. | Use of glutamic acid for preventing/improving functional digestive disorder |
| CN101262796B (en) * | 2005-07-12 | 2011-11-16 | 高露洁-棕榄公司 | Oral care implement having reservior for dispensing active agent |
| RU2008137226A (en) | 2006-03-17 | 2010-04-27 | Байо-Кэнсер Тритмент Интернэшнл Лимитид (Cn) | METHOD AND COMPOSITION FOR PROTECTION FROM RADIATION |
| AU2007249542B2 (en) * | 2006-05-09 | 2009-11-05 | Colgate-Palmolive Company | Oral care regimen |
| BRPI0906451B1 (en) | 2008-02-08 | 2017-01-24 | Colgate Palmolive Co | method to produce arginine bicarbonate |
-
2009
- 2009-02-06 EP EP20090707366 patent/EP2249789A4/en not_active Ceased
- 2009-02-06 WO PCT/US2009/033291 patent/WO2009100265A2/en active Application Filing
- 2009-02-06 BR BRPI0906462-1A patent/BRPI0906462A2/en not_active IP Right Cessation
- 2009-02-06 RU RU2012112933/15A patent/RU2491928C1/en not_active IP Right Cessation
- 2009-02-06 CA CA2711263A patent/CA2711263C/en not_active Expired - Fee Related
- 2009-02-06 US US12/866,630 patent/US10471283B2/en active Active
- 2009-02-06 AR ARP090100427A patent/AR070355A1/en unknown
- 2009-02-06 CN CN201410756129.5A patent/CN104398396A/en active Pending
- 2009-02-06 JP JP2010546016A patent/JP2011511793A/en active Pending
- 2009-02-06 RU RU2010137342/15A patent/RU2455001C2/en not_active IP Right Cessation
- 2009-02-06 MX MX2010005007A patent/MX2010005007A/en active IP Right Grant
- 2009-02-06 AU AU2009212321A patent/AU2009212321B2/en active Active
- 2009-02-06 CN CN2009801048912A patent/CN101951877A/en active Pending
- 2009-02-06 TW TW098103771A patent/TWI409084B/en not_active IP Right Cessation
- 2009-02-06 MY MYPI2010002073A patent/MY157782A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104398396A (en) | 2015-03-11 |
| CN101951877A (en) | 2011-01-19 |
| EP2249789A4 (en) | 2014-01-15 |
| TWI409084B (en) | 2013-09-21 |
| US10471283B2 (en) | 2019-11-12 |
| AU2009212321A1 (en) | 2009-08-13 |
| RU2455001C2 (en) | 2012-07-10 |
| MY157782A (en) | 2016-07-29 |
| US20110189110A1 (en) | 2011-08-04 |
| RU2491928C1 (en) | 2013-09-10 |
| WO2009100265A2 (en) | 2009-08-13 |
| AU2009212321B2 (en) | 2012-04-19 |
| EP2249789A2 (en) | 2010-11-17 |
| CA2711263A1 (en) | 2009-08-13 |
| AR070355A1 (en) | 2010-03-31 |
| TW200946135A (en) | 2009-11-16 |
| MX2010005007A (en) | 2010-05-27 |
| RU2010137342A (en) | 2012-03-20 |
| BRPI0906462A2 (en) | 2015-07-14 |
| JP2011511793A (en) | 2011-04-14 |
| WO2009100265A3 (en) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009212319B2 (en) | Oral care product and methods of use and manufacture thereof | |
| CA2711263C (en) | Compositions and methods for the treatment of xerostomia | |
| EP2249787B1 (en) | Oral care product and methods of use and manufacture thereof | |
| CA2705298C (en) | Oral care product and methods of use thereof | |
| CA2705606C (en) | Compositions and methods comprising basic amino acid peptides and proteases | |
| CA2806652C (en) | Oral care product and methods of use and manufacture thereof | |
| EP3943064A1 (en) | Oral care product and methods of use and manufacture thereof | |
| US20230181438A1 (en) | Oral Care Product and Methods of Use and Manufacture Thereof | |
| AU2012204031B2 (en) | Oral care product and methods of use and manufacture thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190206 |